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Hox genes encode a family of homeodomain-containing transcription factors that 
are critical for body plan specification and tissue morphogenesis during embryonic 
development. Hoxa9, in particular, is required for adult hematopoiesis in which it 
promotes stem cell renewal and expansion. Most importantly, Hoxa9 is commonly 
dysregulated in various types of acute leukemia, including acute myeloid leukemia (AML), 
and T- and B-precursor acute lymphoblastic leukemia (B-ALL and T-ALL). Together with 
its co-factor MEIS1, HOXA9 plays a causal role in driving leukemic transformation. Hoxa9 
dysregulation is also linked to various types of solid tumors, and both gain and loss of 
function have been implicated in tumorigenesis. Despite its central role, the mechanism 
through which HOXA9 mediates oncogenic transformation remains poorly understood.  
Previous work in our lab found that in a HOXA9/MEIS1-driven AML cell line, 
HOXA9 primarily binds to promoter-distal regions of the genome. Its target regions 
predominately carry the epigenetic signatures indicative of active enhancers. A 
substantial portion of HOXA9 binding sites are co-occupied by lineage-determining 
factors, such as C/EBPα and PU.1. However, it remains unknown 1) whether HOXA9 
drives the formation of active enhancers and globally alters the enhancer landscape; 2) 
whether HOXA9 strictly acts downstream of other transcription factors, or it can play a 
pioneer role and acts upstream of all other transcription factors and chromatin regulators; 
3) if its regulatory functions are conserved in other cell lineages. 
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To address these questions, I show that in the myeloid lineage, HOXA9/MEIS1-
transformed cells are characterized by significant alterations of the enhancer landscape 
and exhibit prominent emergence of de novo enhancers. These de novo enhancers are 
absent of enhancer modifications in any hematopoietic cells, and are associated with 
activation of a leukemia-specific transcription program. HOXA9 acts as a pioneer factor at 
these de novo regions and is required for the recruitment of myeloid lineage factor 
C/EBP while it is dispensable for the formation of the normal hematopoietic enhancers. 
Together, these results suggest an active role of HOXA9 in altering enhancer landscapes 
during leukemic transformation.  
To explore the mechanisms of HOXA9-mediated enhancer formation, I assessed 
the role of the histone H3K4 methyltransferase MLL3/MLL4 complex in this alteration of 
enhancer landscape. Using immunoprecipitation and ChIP-seq analysis, I found physical 
interaction between HOXA9 and the MLL3/MLL4 complex. In addition, I determined that 
the MLL3/MLL4 complex is required for formation of de novo enhancers, as well as for in 
vivo leukemogenesis driven by HOXA9/MEIS1. Collectively, these findings provide strong 
evidence for an essential role for the MLL3/MLL4 complex in HOXA9-mediated leukemic 
transformation. 
I have also collected preliminary data pertaining to HOXA9’s function in other cell 
lineages. I found that HOXA9 localizes to active enhancer regions in B-lineage leukemia 
cells and reshape the enhancer landscape; hence, confirming HOXA9’s enhancer binding 
characteristics. Furthermore, I discovered that HOXA9 efficiently blocks the adipogenic 
program in pre-adipocytes by preventing the upregulation of the key adipogenesis factor, 
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Pparg. These data highlight a coherent role for HOXA9 in regulating gene expression and 
modulating cellular differentiation across different lineages.  
In summary, this dissertation reveals a previously uncharacterized role of HOXA9 
in leukemogenesis and cellular transformation, and provides a strong rationale for 
targeting the HOXA9-collaborating chromatin modulators, as well as the leukemia-









1.1 Hox genes – an overview 
1.1.1 Evolution of Hox genes 
Hox genes encode a family of evolutionarily conserved homeodomain-containing 
transcription factors that control critical processes in early development, such as body 
plan establishment, cell identity specification and organogenesis [1, 2]. Hox genes were 
first found to cause homeotic transformation in Drosophila, where the mutation of a 
single Hox gene was sufficient to cause homeotic transformation - that is, changing one 
body segment to another [3]. Since this early discovery, homeotic transformation 
triggered by mutations or misexpression of Hox genes has been identified in several 
other organisms, including chicken, mice, and human [4-6]. This conserved homeotic 
change testifies to the importance of Hox genes for proper development across many 
species. 
While invertebrates generally have one cluster of Hox genes, vertebrates have 
several Hox clusters, likely due to multiple duplication events of the entire cluster during 
evolution. In mammals, the four paralogous clusters of Hox genes, named A, B, C and D, 
are located on separate chromosomes [7]. Within each cluster, Hox genes are numbered 




the same number have the highest sequence similarity. Hox genes are arranged 
typically according to their expression pattern along the anterior-posterior (A-P) axis, 
which is called “spatial collinearity”: genes towards the 3’ end of a cluster are expressed 
anteriorly in an embryo; those towards the 5’ end are expressed progressively more 
posteriorly. Their spatial arrangement also correlates with the expression temporal 
sequence, which is called “temporal collinearity”. The 3’ genes are activated earlier and 
expressed in strictly the anterior domains. The 5’ genes are expressed later, and 
function progressively more posteriorly in the developing embryo [8]. The coordinated 
spatiotemporal control of Hox gene expression is vital to the distinct body structure 





Figure 0-1 The spatial and function collinearity of Hox genes 
A schematic showing the homology between Drosophila and human Hox genes. 
The four clusters of Hox genes are located on different chromosomes: 7p15 (A), 17q21 
(B), 12q13 (C) and 2q31 (D), evolved from repeated duplications from one cluster of 
ancestral genes [9]. The coloration of the genes represents the correspondence 
between their genomic arrangements and their functional zone along the anterior-
posterior axis in development. Schematic modified from Pearson Education, 2009. 
1.1.2 The regulation of Hox genes in development 
Among metazoans, each species presents divergent morphologies, but relies on 
the same Hox regulation system to establish their body plan. Thus, the expression 
collinearity with the genomic organization of Hox clusters has fascinated generations of 




tight, coordinated control of Hox gene expression. Global chromatin structure [10, 11], 
histone modifications [12], availability of certain transcription factors, long non-coding 
RNAs (lncRNAs) [13], as well as Hox gene themselves [14], all play a role in the highly 
organized expression regulation. 
Polycomb (PcG) and trithorax (TrxG) group genes are the key regulators of Hox 
loci. These genes encode histone methyltransferases that implement the post-
translational modifications (PTMs) on histones, and thus control the local chromatin 
conformation. PcG-mediated chromatin compaction is achieved through the synergized 
actions of Polycomb-Repressive Complex 1 and 2 (PRC1 and PRC2). PRC2 triggers 
histone H3 lysine 27 trimethylation (H3K27me3), an epigenetic mark closely related to 
gene repression, while PRC1 is recruited to the trimethylated regions and mediates 
ubiquitination of H2A lysine 119. By contrast, TrxG protein complexes mediate the 
trimethylation of H3 lysine 4 (H3K4me3) at gene promoter regions, a histone PTM 
commonly associated with gene activation. Therefore, PcG and TrxG complexes 
antagonize with each other to exert dynamic control over the target genomic regions 
[15]. It was first discovered in Drosophila that in early embryogenesis, maternally 
supplied factors pre-determine the chromatin configuration of Hox clusters [16]. In late 
embryogenesis, this configuration is either maintained by PcG family proteins or 
counteracted by TrxG family members to achieve proper gene activation or repression 
in a highly regulated manner [17]. In mice, sequential activation of Hox genes is 
observed at the HoxD cluster, as a result of the dynamic interplay between PcG and 




H3K27me3 is accompanied by gain of H3K4me1, which leads to a conversion between 
the two epigenetic states and a shift of transcriptionally activated domain [18].  
The epigenetic state switch is facilitated by the three-dimensional chromatin 
architecture of the Hox gene clusters. First discovered with Fluorescent in situ 
Hybridization (FISH) [19] then more fully characterized with Chromatin Conformation 
Capture (3C)-derived technologies [10, 11], Hox gene clusters are differentially 
organized in accordance with the gene transcription activity. In embryonic stem cells 
(ESC) where Hox genes are uniformly silenced, the chromatin segment hosting all Hox 
genes is compacted into a single spatial structure with bivalent epigenetic marks, as 
were seen with widespread interaction among various genomic loci. Later when Hox 
genes are differentially activated and required for morphogenesis, the entire 
chromosomal region is organized into bimodal compartments and segregated into 
activated or repressed domains with different histone PTMs (reviewed in [20]). 
Besides, vertebrates also acquired additional regulatory mechanisms to adapt to 
the increasing demand of spatiotemporal gene regulation. These modalities are 
enhancer elements located outside of the Hox clusters, scattered over a large gene 
dessert on either side of Hox genes [21, 22]. One example to illustrate this additional 
mechanism is the regulation of posterior HoxD cluster genes (Hoxd9-13) during limb 
generation. These genes are required for the patterning of both proximal (arm and leg) 
and distal (hand and foot) segment. Initially during the development of proximal limb, 
HoxD genes form interaction loop with potential regulatory elements located on the 
telomeric side of the Hox cluster [23]. Later in the distal limb formation, a centromeric 




interaction with the gene cluster. These active enhancer elements first play a partially 
redundant role in activating posterior HoxD genes, but are progressively silenced as the 
distal limb formation completes [11]. 
Moreover, Hox gene expression is further modulated with non-coding RNAs, 
micro RNAs and metabolic signals, which compounds the transcriptional complexity. 
For instance, HOTAIR, the lncRNA transcribed from the HoxC cluster, interacts with 
both PRC2 and the histone demethylase LSD1 to maintain repression of the HoxD 
cluster in human [24]. Such a multilayered regulatory network may both confer a tight 
spatiotemporal control on Hox gene expression, and allow some regulatory flexibility 
during development and evolution [25].  
1.1.3 The function of Hox genes in homeosis 
The mutation of the extra sex combs (esc) gene, a member of the PcG family, 
led to the discovery of the functional hierarchy among Hox genes. Loss of ecs causes 
simultaneous expression of several homeotic genes in the all domains along the A-P 
axis. Interestingly, the most posterior genes dictate the resulting segment identity. For 
instance, the head and thoracic segment in larvae with ecs mutation experience 
posterior transformation and develop into the abdominal segment, A8, which is specified 
by the most posteriorly-acting gene, abd-B. In the absence of abd-B, the second most 
posterior gene, abd-A, conferred the segment A4 identity to all other domains. When all 
abdominal genes are eliminated, the larva becomes a chain of thoracic segments, 
which are specified by Scr and Antp. When the five most posterior genes were all 




function study suggests a functional hierarchy among the homeotic genes: the posterior 
genes in general had the comparatively dominant role over the anterior genes [26, 27].  
Further genetic gain- and loss-of-function analyses in Drosophila corroborated 
this finding. In general, loss-of-function mutations cause anterior homeotic 
transformations, while gain-of-function results in posterior transformation [1, 3, 28]. This 
is especially true for the most posterior factors, Antp, Ubx, abd-A, and abd-B genes, 
although some exceptions to this pattern do exist for the anterior paralogs.  
The functional hierarchy is also present in vertebrates, which is termed posterior 
prevalence. Systematic loss-of-function studies in mice revealed that the removal of 
most anterior Hox genes (between paralog 1-6) affects morphogenesis mainly in the 
cervical structures, although they are expressed in more posterior domains as well [29, 
30]. In contrast, inactivation of Hoxd13 causes a prevalent phenotypical alteration in all 
sites with normal Hoxd13 expression [31]. Gain-of-function mutations primarily generate 
phenotypes under the same principle: when posterior Hox genes are ectopically 
expressed in anterior domains, such as Hoxd4 in the domains of Hoxa1, those domains 
more likely experience posterior homeotic transformation [32], while expression of 
anterior Hox genes in posterior domains produces less drastic transformations. 
Deviations from this principle have also been described, likely due to the complexity of 
vertebrate gene regulation (systematically reviewed in [7, 33]).   
Altogether, the series of cross-species genetic studies demonstrate a principal 
role of posterior homeotic genes. They also suggest that besides the tight 




intrinsic mechanistic differences to exert their instructive role on morphogenesis and 
body patterning in development. 
1.2  The molecular functions of HOX proteins 
1.2.1 Protein structure and motif recognition 
Mammalian HOX proteins are relatively small, with molecular weight ranging 
from 25kDa to 49kDa. These proteins are encoded on two exons, with the 
homeodomain generally present within the second exon. The 60-amino acid 
homeodomain shows high sequence conservation, especially among paralogs. Another 
conserved motif is a hexapeptide (HX) upstream of the homeodomain that interacts with 
TALE (Three Amino-acid Loop Extension) family proteins, which act as cofactors for 
concerted DNA binding [34]. Sequences outside of the homeodomain and the HX motif 
diverge substantially, which include an acidic tail at the C-terminus, a linker region 
between the homeodomain and the hexapeptide, and a highly variable N-terminus. 
While their functions are largely unknown, these non-conserved regions are reported to 
contain PTMs and interact with other transcription regulators to orchestrate the 
transcriptional response [35]. 
The homeodomain has three alpha helices and a flexible N-terminal arm. Helix 3 
makes sequence-specific contact in the DNA major groove, N-terminal arm with the 
minor groove, while helix 1 and 2 form the Helix-Turn-Helix (HTH) structure and lie 
above the DNA [34]. The homeodomains of HOX proteins in general bind to a very 
similar set of AT-rich sequences in vitro. Isoleucine (Ile) 47, glutamine (Gln) 50, 




and are responsible for making direct or water-mediated contacts with these sequence 
motifs [36, 37]. Arginine (Arg) 5 in the N-terminal arm is the most conserved residue 
binding in the minor groove. 
The core motif for HOX recognition is 5’-TAAT[t/g][a/g]-3’, with the exception of 
abd-B paralogs (5’-TTAT[t/g][a/g]-3’) [38]. The specific binding of the first two bases 
pairs (5’-TTTAT-3’) are imparted by the Arg 5 in the N-terminal arm. Because of the 
short and well-ordered linker, the N-terminal arm can also induce minor groove 
compression and DNA bending, a phenomenon specific to the posterior Abd-B paralogs 
such as HOXA9. The later three 3’ base pairs (5’-TTTAT-3’) are specified by helix 3 in 
the homeodomain. Asn 51 interacts with the adenosine at the fourth position of the 
motif. For Abd-B paralogs, because of DNA bending and contribution from the minor 
groove, Asn 51 also forms van der Waals interaction with the thymidine at the third 
position, which explains the slightly different motif recognition pattern [39]. Ile 47 and 
Glu 50 together specify the first base tolerated at base pair 3’ of the core motif, and Met 
54 specifies the second base in the recognition motif.  
These structural studies showed that posterior Abd-B paralog HOX proteins have 
greater number of nonspecific interactions with DNA than the anterior proteins, which 
may explain the increased DNA binding affinity observed in HOXA9 as compared with 
HOXB1 [36, 37, 39]. This increased contact with DNA may also be an important 
mechanism for the functional hierarchy observed in Drosophila and mice. Because of 
this affinity difference, the stronger interaction with DNA may allow the posterior HOX 




Another phenotypic study corroborates the idea that the homeodomains of 
different HOX paralogs may bear some intrinsic differences in gene regulation, 
independent from the hexapeptide-mediated cofactor interactions or N-terminus-
mediated transactivation. The over expression of HOXA1 or HOXA9 drive leukemia 
development with significantly different aggressiveness and latency. Using these two 
leukemia models, Constanze et al found that an exchange of their homeodomain is 
sufficient to convert the slow progressing leukemia of HOXA1 into the aggressive one 
induced by HOXA9. Similar gene expression profiles were established by the 
homeodomain of HOXA9 regardless of the remaining protein sequences, suggesting 








Figure 0-2 The motifs of different HOX paralogs 
HOX protein DNA-binding motifs as determined by bacteria one-hybrid (B1H, left) 
or various in vivo platforms (in vivo, right) showing the slightly different binding 
preference for the most anterior (HOX1) and most posterior (HOX9-13), as compared to 





1.2.2 TALE family cofactors and HOX latent specificity 
TALE family proteins were identified nearly simultaneously with HOX proteins as 
their cofactors and modulators for DNA binding and in vivo functions. These includes 
PBC proteins, such as CEH in C. elegans, Extradenticles (Ext) in Drosophila and PBX 
in mammals, and HMP proteins, such as UNC in C. elegans, Homothorax (Hth) in 
Drosophila as well as MEIS/PREP in mammals (Figure 1.3). TALE proteins are 
characterized by a highly conserved homeodomain that differs from the canonical 
homeodomain by an insertion of three amino-acid loop extension (TALE) motif between 
helix 1 and 2 in the homeodomain. The traditional view of the HOX-TALE interaction is 
that HOX proteins insert the conserved hexapeptide motif into hydrophobic pocket of 
TALE proteins, which is comprised of the TALE motif and residues of helix 1 and 3. The 
HOX hexapeptide motif contains a conserved Y/E-P/D-W-M sequence, in which the 
tryptophan (W) residue is essential for the interaction with the hexapeptide-binding 
pocket of TALE. However, subsequent studies show that the posterior Abd-B or HOX 
paralogs group 9-13 adopts a different conformation and relies on the single W to 
mediate the interaction. Moreover, residues in the non-conserved regions, the acidic C-
terminus and the linker regions, are also shown to provide additional surface and 





Figure 0-3 The interaction between HOX, HMP and PBC proteins 
 (A) Names of HOX protein co-factor orthologs in C. elegans, Drosophila and 
vertebrates; (B) Motifs in HOX proteins to mediate interactions with PBC and HMP 
proteins. (Figure modified from [35]) 
The interaction with TALE family factors is thought to enhance both specificity 
and affinity of HOX proteins’ DNA binding. These HOX cofactors have been shown to 
form trimeric Hox/Exd/Hth (HOX/PBX/MEIS) complexes that confer functional specificity 
in vivo [42-45]. Using biochemical tools, it has been demonstrated that the addition of 
TALE factors can result in a shift in HOX binding preference. Thus, the term “latent 
specificity” was coined to describe the concept that binding with cofactors in a complex 
changes sequence specificity. This concept was tested comprehensively in a recent 
study using SELEX-seq (Systematic Evolution of Ligands by EXponential enrichment 
followed by sequencing). Briefly, a pool of double-stranded DNA oligomers was 
selected with purified Drosophila Hox monomers alone or Hox-Ext complexes and then 
sequenced to determine their preferred DNA motifs. It is revealed that although Hox 




preferences. The preferred core motif can be classified into three clusters along the A-P 
axis: the anterior (lab, pb), middle (Dfd and Scr) and posterior Hox factors (Antp, Ubx, 
Abd-A and Abd-B). Anterior Hox factors select sequences with a narrow minor groove, 
while posterior Hox factors target sequences with wider minor groove. Differentiating 
preferences for sequences flanking the Hox core motif have also been found, especially 
for anterior Hox factors. These differences are clearly dependent upon the dimerization 
with TALE proteins [46].  
Using structural and biochemical tools, it has been demonstrated that the 
interaction with PBC proteins allow the variable regions of Hox proteins to contribute to 
DNA binding [47, 48]. One example using the Src-Exd complex demonstrated this 
principle. At a selective Src-Exd binding site, insertion of certain Src-specific residues 
into the DNA minor groove changes the electrostatic environment which favors binding 
of basic residues. These residues, in the N-terminal arm and immediate 3’ linker region, 
are otherwise disordered at canonical Hox-Exd binding sites. This allosteric change 
suggests that correct positioning of the variable regions of Hox, in concert with Exd 
factors, is most critical for Hox binding at non-canonical/paralog-specific sites [49].  
The study described above with Scr-Exd is also in agreement with the recent 
hypothesis that the specificity of Hox proteins primarily manifests at low-affinity binding 
sites: while canonical Hox binding sites only require the conserved regions of 
homeodomain, low-affinity sites depend on paralog-specific residues to mediate stable 
contact. Another piece of evidence comes from Croker et al [50]: they identified a 
cluster of low-affinity Ubx-Exd binding sites in enhancers of the Drosophila shavenbaby 




high-affinity ones, it allows the activation of the enhancer by other Hox paralogs. These 
low-affinity sites may offer regulatory advantage over high-affinity sites for fine-tuning 
the gene expression [50-52].  
Altogether, these studies have revealed several additional layers of mechanisms 
that HOX complexes exploit to achieve specificity beyond the simple contact with DNA 
sequence motifs. 
1.2.3 Collaboration with epigenetic and transcriptional machineries 
There is no known HOX target gene whose expression pattern is controlled by 
HOX proteins alone [53]. While TALE cofactors clearly contribute to the DNA motif 
recognition, the HOX-TALE protein complexes also employ other collaborating proteins 
to orchestrate the transcriptional response [54]. It has been proposed that the assembly 
of multi-component complexes at HOX-regulated cis-elements, which includes 
transcriptional machineries, the mediator complex and chromatin remodelers, is 
indispensable for modulating HOX-mediated transcriptional outcomes [41].  
It was discovered early on that HOX proteins can regulate target genes by either 
activating or repressing transcription [55]. The distinct regulatory functions are likely 
executed in collaboration with different interaction partners. One well-known example is 
the regulation of mammalian osteocalcin expression [56-58]. Osteocalcin gene promoter 
contains adjacent HOX and PBX consensus motifs. In pre-osteoblast, PBX1 and 
HOXA10 are both bound at this promoter and together recruit histone deacetylase 
(HDAC), and as a result, maintain a repressive chromatin conformation. As pre-




osteocalcin promoter. HOXA10 alone recruits CBP/p300 histone acetyltransferase 
(HAT) instead, and activate the gene expression. This example illustrates that HOX-
PBX heterodimer simultaneously recruits HAT and HDAC with the overall outcome 
determined by the ratio of these activities. In addition, it suggests that the availability of 
certain cofactors can either enhance or reverse the direction of transcription regulation 
mediated by HOX factors. 
Multiple HOX family proteins, including HOXA9, HOXB1, HOXB7 and HOXD4 
[59-61], have been shown to interact with CBP/p300 complex and mediate the histone 
acetylation of their target sites. Likewise, HOX cofactor MEIS1 recruits CREB1/CBP via 
its C-terminal regions [62]. While the activity of HOX-PBX complexes may be dependent 
on their relative ratio, co-binding of MEIS in the complex seems to shift the activity 
balance towards the active side [59, 63]. In addition, several HOX paralogs have been 
found to recruit repressive complexes, such as Groucho co-repressor proteins in 
Drosophila [64, 65] and G9a histone H3 lysine 9 methyltransferase in mammalian cells 
[66].  
The direct association with the Mediator (MED) complex has also been reported 
for Drosophila Hox proteins. MED complex is a multi-subunit protein machinery: some 
of its subunits interact with DNA and other DNA-bound transcription factors, while 
others bridge RNA polymerase II (Pol II) to the transcription start site. Analysis with 
Drosophila pd and Src revealed that these Hox proteins make direct contact with 
Med19, a subunit of MED complex, via the homeodomains. Mutation of Med19 affects 
Hox target gene transcription and abolishes its developmental activity, suggesting that 




evidence that Hox proteins can serve an interface for the targeting of general 
transcriptional machinery.   
In addition to the role in Pol II recruitment, some members of HOX family can 
also modulate the activity of Pol II. In early zebrafish embryo, Hoxb1b, Pbx and 
Prep/Meis act in cooperation to regulate the expression of Hoxb1a. In zygote, 
maternally-supplied Pbx and Prep are loaded on Hoxb1a promoter, which facilitate the 
implementation of histone acetylation marks and the recruitment of Pol II. However, in 
this phase without Hoxb1b, Pol II is maintained in a poised state that is insufficient to 
initiate transcription. Later in embryogenesis, Hoxb1b is expressed and loaded on 
Hoxb1a promoter, where it promotes the phosphorylation of Pol II and the subsequent 
transcription elongation of Hoxb1a [68, 69]. The regulation of Pol II activity adds another 
level of control to Hox-dependent gene expression.    
 In sum, Hox family proteins utilize diverse mechanisms to modulate gene 
transcription involving the assembly of multi-protein complexes; these complexes are 
required on HOX-regulated cis-elements to produce the proper expression outcomes. 
1.2.4 Impact on chromatin accessibility 
Chromatin is by default packaged into nucleosomes that restricts protein binding 
and interferes with DNA-templated processes such as transcription [70]. In order for 
Hox factors to exert gene regulation function, they must be able to gain access to 
histone-free DNA. Given their transcription regulation roles, it is then a logical next-step 
to examine whether their functions are restricted to pre-accessible chromatin, or 




accessibility and drive relaxation of chromatin. The prevailing idea is that the genome-
wide targeting of HOX factors is strongly influenced by the chromatin accessibility of a 
specific tissue; lineage-determining transcription factors establish the chromatin 
landscape and thus allow a distinct subset of targets to become accessible by Hox [35, 
71]. However, this view is somewhat inconsistent with the strong homeotic phenotype 
driven by Hox mutations or misexpression. Since cell type specification is one key role 
of HOX factors (see discussions above), they are presumably able to play a role in 
defining the lineage context for transcriptional regulation.   
Direct evidence came from a chromatin accessibility test in Drosophila cell 
culture. It is revealed that Hox proteins may differ in their ability to associate with 
nucleosome-bound DNA [72]. In this study, a Drosophila embryonic cell line was 
transiently transfected with Ubx, Abd-A or Abd-B, and their global binding was assessed 
and compared with DNase I hypersensitive sites prior to transfection. While the vast 
majority (94%) of Ubx and Abd-A binding sites occurred within the pre-accessible 
regions, a significant portion (25%) of Abd-B occupied DNase I-insensitive, previously 
closed chromatin regions. This suggests that the ability to access closed chromatin 
regions varies among Hox factors. 
Although the expression of Ubx alone does not induce substantial change in 
global chromatin accessibility, co-binding with cofactor Exd and Hth may collectively 
drive chromatin remodeling and have a greater impact on genome-wide DNA 
conformation. Indeed, when Hth is co-transfected with Ubx into the Drosophila cell line, 
the number of Ubx peaks doubled and the percentage of Ubx binding on previously 




the additional Ubx binding sites, suggesting a collaborative effect between Hox and its 
TALE cofactors [72].  Together, these findings indicate that although Hox family proteins 
may differ in the ability to globally remodel DNA accessibility, complexing with Exd/PBX 
or Hth/MEIS cofactors will increase their potential to reposition nucleosomes and 
facilitate their interaction with DNA sequence. 
 There is also evidence suggesting that HOX proteins may work in conjunction 
with SWI/SNF chromatin remodeling complexes. In a murine cell line, the ATPase 
subunit of the SWI/SNF complex (Brg1) not only co-immunoprecipitates with HOXA9, 
but also co-localizes with HOXA9 at hundreds of promoter-distal regulatory elements 
[73]. Although further evidence needs to be collected, this serves as our first clue that at 
specific sites, Hox proteins may act jointly with the ATP-dependent chromatin 
remodelers and render the nucleosome-bound DNA more accessible to other 
transcriptional regulators. 
1.3  HOXA9 in normal development and malignant transformation 
Amplification of the ancestral Abd-B gene likely happened prior to the duplication 
of the entire Hox cluster. This singular amplification event may be linked to the 
emergence of the appendicular system during evolution [74]. Together with subsequent 
duplication of the entire Hox cluster, it produced four different paralog groups (9-13) as 
we now know for vertebrates (Figure 1.1).  These genes exert critical functions in both 




1.3.1 Normal function in hematopoiesis 
HOXA9, in particular, is extensively expressed in the developing fetus [75]. Its 
transcripts are also detected in various adult tissues, including bone marrow, colon, 
kidney, prostate and skeletal muscles [76]. Like most of the posterior Hox genes, Hoxa9 
is highly expressed in the CD34+ population of the hematopoietic progenitors, and its 
down-regulation is associated with hematopoietic differentiation [77]. In embryonic stem 
cells (ESC), HOXA9 promotes the hematopoietic differentiation into hematopoietic stem 
cells (HSC), and enhances the commitment of precursors into primitive and mature 
blood cells [78]. While strong over expression of Hoxa9 in the hematopoietic tissues 
causes embryonic lethality, lower level of enforced expression lead to an expansion of 
the stem cell and progenitor populations, with a concomitant block on differentiation. 
Over extended time (three to six months) or with additional mutations, mice with Hoxa9 
over expression in bone marrow develop acute myeloid or T-cell lymphoblastic leukemia 
[79, 80]. However, possibly as a consequence of functional redundancy, disruption of 
this gene results in minor phenotypical changes. Mice with Hoxa9 mutations show 
normal health and weight, although have decreased size and cellularity in the spleen 
and thymus. The most drastic phenotype is displayed in the hematopoietic 
compartment, which has 30-40% of reduction in the number of B cells, T cells and 
granulocytes. Hoxa9-deficient cells also have repopulation deficiencies compared to 
wild type cells, which include reductions in common myeloid progenitors (CMP), 
granulocyte/monocyte precursors (GMP), common lymphoid precursors (CLP) and 
lymphoid precursors (pro- and pre-B cells, pro-T cells) [81-83]. Mice transplanted with 




than 10-fold reduction of HSC in the bone marrow [80]. Together, these results indicate 
that the stem-cell capacity of Hoxa9-deficient cells is impaired, which underscores the 
importance of Hoxa9 in controlling HSC expansion and self-renewal. 
1.3.2 The role of HOXA9 in leukemia 
Overview 
HOXA9 is most intensively studied in the case of acute leukemia. More than 50% 
of acute myeloid leukemia cases have 2-8-fold increase of Hoxa9 expression than 
healthy controls, as a result of various genetic abnormalities [54, 84]. In acute 
lymphoblastic leukemia (ALL) cases, such as pro-B cell ALL or pro-T cell ALL, Hoxa9 
over expression is more strictly associated with certain types of gene rearrangements 
[85, 86]. High Hoxa9 expression is associated with intermediate to unfavorable 
prognosis [87], and one study found that Hoxa9 is the most prognostic factor for poor 
prognosis [88]. Admittedly, elevated expression of Hoxa9 is often the consequence of 
upstream genetic alterations, which themselves have an adverse prognosis [73]. 
Nonetheless, the fact that a range of leukemogenic programs all converge to drive the 
over expression or over activation of Hoxa9 attests to its critical role in hematological 
malignancies. 
Upstream regulators of Hoxa9 
Acute myelogenous leukemia 
A variety of genetic aberrations lead to the over expression of Hoxa9 in AML. 
Among them, MLL-related leukemias are the most intensively studied. These leukemias 




MLL1. Wild type MLL1 encodes a histone H3K4 methyltransferase, which is required for 
promoter activation of Hoxa9 in normal hematopoiesis as well as in MLL-related 
leukemia [89]. Leukemia with genetic alterations at this locus constitute 70% of pediatric 
AML and 10% of adult AML, which include duplication, amplification and chromosome 
translocation [90]. Over 80 translocation partners have been discovered in MLL-related 
leukemia, although in most cases, the translocations involve one of the six most 
common partners: AF4 [t(4;11)], AF9 [t(9;11)], ENL [t(11;19)(q23;p13.3)], AF10 
[t(10;11)], ELL [t(11;19)(q23,p13.1)], or AF6 [t(6;11)] [91]. Among them, AF4, AF9, ENL 
and ELL have been implicated in transcriptional activation or elongation. In addition, 
DOT1L, the histone H3 lysine 79 methyltransferase, interacts with MLL-fusion proteins, 
which can contribute to the promoter methylation of MLL-fusion target genes [92]. Since 
both wild type MLL1 and MLL-fusion bind to the Hoxa9 promoter [93], all these 
transcriptional activation mechanisms have been directly linked to Hoxa9 upregulation 
in MLL-fusion leukemia.  
 HOXA9 is also involved in chromosomal translocations in leukemia. The most 
frequent fusion partner is NUP98, a member of the nuclear pore family. NUP98-HOXA9 
induces leukemia with an extended latency (11-12 months). However, co-expression 
with Meis1 significantly accelerates disease progression, suggesting a conserved 
mechanism for HOXA9 and HOXA9-fusion to drive leukemia. 
 Several other mutations have been found to correlate with elevated Hoxa9 
expression, although the mechanisms are less clear. One of the most common genetic 
abnormalities in AML is nucleophosmin1 mutation, a protein normally resides in the 




unknown mechanisms, contributes to HOXA9 upregulation [73, 94].  Several additional 
mechanisms have been linked to Hoxa9 upregulation, including EZH2 mutation [95], 
CDX2 over expression [96], MOZ-fusion [97] and CALM-AF10 fusion [98, 99].  
Acute lymphoblastic leukemia 
  Dysregulation of Hoxa9 is also reported in ALL, including both B- and T-
precursor ALL (B-ALL and T-ALL), which are commonly associated with MLL 
translocations [100]. In addition, the T-ALL cases with CALM-AF10 translocation display 
Hoxa9 upregulation [101]. HOXA9 can also form chimeric fusion products with T cell 
receptors (HOXA/TCR) [98, 102], adding to the diversity of HOXA9-related 
abnormalities in ALL. 
Loss of function studies 
 MLL-related leukemia is addicted to both HOXA9 and its cofactor MEIS1 both in 
AML and ALL. Knocking-down of either gene exhibits largely overlapped phenotypes, 
including apoptosis, cell cycle arrest, cellular differentiation and reduced leukemogenic 
potential [103-106]. An in vivo study revealed that although homing capacity was intact, 
their ability to colonize bone marrow was undermined [107]. Therefore, maintenance of 
the leukemic state requires over expression of both genes, regardless of the lineage 
specification. Moreover, MLL-AF9 fusion protein is unable to transform HOXA9-deficient 
bone marrow cells. The similar phenotypes shared by knocking down both genes 
suggest that HOXA9 and MEIS1 collaborate and function in the same oncogenic 




Gain of function studies 
As described earlier, over expression of Hoxa9 in murine BM results in AML, and 
the disease latency inversely correlates with the dose of Hoxa9-expressing cells [80]. 
Thorsteinsdottir et al performed a thorough analysis on the hematopoietic phenotypes of 
Hoxa9-overexpressing cells. They found that murine BM transduced with Hoxa9 gave 
rise to an expanded myeloid compartment with increases in both mature cells and 
myeloid progenitors. In contrast, Hoxa9 over expression suppresses B lymphopoiesis in 
the chimeric model as well as in two transgenic models. Hoxa9-overexpressing BM 
produces very few pre-B lymphoid progenitor cells, and those pre-B cells generate 
fewer and smaller pre-B colonies than their wild type controls. Hoxa9 alone can 
immortalize BM progenitors in vitro, but they are myeloid-lineage restricted. Collectively, 
these findings indicate that Hoxa9 over expression skews hematopoiesis towards the 
myeloid lineage in mice [80].  
Although Hoxa9 itself is only weakly oncogenic, co-expression of the Hth family 
cofactor Meis1 along with Hoxa9 induces rapid leukemia development in mice [108]. 
Unlike Hoxa9-only cells that are primarily restricted to the myeloid lineage, the 
Hoxa9/Meis1 cells (HM cells) maintain multipotent potential and can be induced into 
either myeloid or lymphoid lineage [109]. It was also discovered that the tumor-initiating 
capacity of HM cells exists in all phenotypic compartments, including the myeloid, the 
lymphoid and the lineage-negative population [110]. HM cells have increased 
expression of HSC-specific genes, such as Flt3 and Cd34, as well as the lymphoid 
lineage-inducing of IL-7 receptor. Consequently, these cells proliferate in response to 




expression of Meis1 alone does not transform BM cells [111].  However, co-expression 
of Meis1 and Hoxa9 is frequently found in human acute leukemias, suggesting a 
functional cooperation between the two factors [100, 112]. The aggressive leukemia 
driven by Hoxa9 and Meis1 is also a useful tool to study the mechanisms of Hoxa9-
dependent leukemia. 
HOXA9 targets in leukemia  
The study of HOXA9-mediated leukemogenic mechanisms has been strongly 
accelerated by the development of high-throughput technologies. These technologies 
enable the delineation of HOXA9-responsive regulatory elements on a genome-wide 
scale. In two independent studies of a HOXA9/MEIS1-transformed AML cell, the 
genome-wide binding sites of HOXA9 were identified using ChIP-on-chip or ChIP-seq 
[54, 61]. It was discovered that HOXA9 primarily binds on promoter-distal (>2kb from 
transcriptional start sites) regulatory sequences, which show a high degree of 
evolutionary conservation. These HOXA9-target sites are found to be associated with 
certain protooncogenes that have been implicated in hematological malignancies, such 
as Erg, Flt3 and Myb [109, 113-115]. Using an inducible model of HOXA9, these studies 
found that nearly equal numbers of genes were up-regulated and down-regulated upon 
loss of HOXA9, suggesting that HOXA9 may employ distinct regulation mechanisms to 
modulate gene expression (see Chapter 1.2.3). Consistent with its oncogenic role, 
HOXA9 in general up-regulates pro-proliferative and anti-apoptotic genes, while 
repressing myeloid differentiation and immune response programs [73].  
 A number of studies have examined HOXA9 regulation of individual genes. In 




Pim1, and positively regulates Pim1 expression. It was then proposed that Pim1 may 
act as a mediator and execute oncogenic and anti-apoptotic functions in leukemia [116]. 
In both myeloid and B-lineage leukemia, HOXA9 upregulates insulin-like growth factor, 
Igf-1, which in turn promotes survival and transformation potential of leukemia cells 
[115, 117]. Furthermore, HOXA9 activates the Rho family of GTPases, including the 
signaling protein RAC1, through upregulating Vav2 expression [118]. Taken together, 
HOXA9-targets are implicated in various signaling pathways, molecular functions and 
metabolic processes, which implies that HOXA9 regulates a transcriptional network to 
promote leukemogenesis. 
1.3.3 The role of HOXA9 in other types of cancer  
Aside from leukemia, Hoxa9 misexpression is also implicated in many other 
cancers, including ovarian, prostate, colon, breast and bladder cancer, as well as 
hepatocellular carcinoma and non-small cell lung cancer [119-129]. The effect of 
HOXA9 on carcinogenesis can be either positive or negative: in ovarian, prostate and 
colon cancer, elevated HOXA9 expression is found to be associated with advanced 
disease status or metastasis, while in bladder cancer and hepatocellular carcinoma, 
DNA hypermethylaton at Hoxa9 promoter is an indicator of poor prognosis, which 
suggests that tumor samples had reduced Hoxa9 expression compared with normal 
tissues. Furthermore, sustained expression of HOXA9 is required for modulating the 
breast cancer tumor suppressor BRCA1, and loss of HOXA9 promotes tumor 
progression, metastasis, and patient mortality [126]. 
It is clear from the wide variety of malignancies with dysregulated HOXA9 




tuned HOXA9 expression is critical for the maintenance of tissue homeostasis. 
Therefore, understanding the regulation mechanisms of HOXA9 on downstream targets 
will shed light on disease mechanisms and provide novel avenues for therapeutic 
design. While the dysregulation of HOX genes can be resulted from a variety of 
mechanisms, defining the common and unique characteristics of HOXA9 protein 
function will undoubtedly give insights into the general principles of HOX biology that 
can be applied to various diseases with misregulated HOX expression. 
 
1.4  Epigenetic regulation 
1.4.1 Epigenetic regulation – an overview 
In a multicellular organism, almost every single cell shares the identical genome, 
and yet they generate diverse cell types that have distinct and inheritable 
characteristics. The reason behind this paradox falls into the realm of epigenetics. The 
term “epigenetics” was coined in 1942 by Conrad Waddingon as “the branch of biology 
which studies the casual interactions between genes and their products, which brings 
the phenotype into being”. In line of this concept, the study of epigenetics focuses on 
how gene expression is regulated without alterations in DNA sequence [130]. According 
to Waddington, cellular differentiation can be described as the decision-making process 
that takes the individual cell into different trajectories. The diverse trajectories together 





Figure 0-4 Waddington’s Classical Epigenetic Landscape 
This is a visual metaphor that portrays how one single cell (represented by a ball 
on the top) follows different permitted paths into different final cell states or fates (Figure 
modified from [131]). 
 
 The core molecular actors that play an indispensable role are covalent and non-
covalent modifications on DNA and histones – the proteins intimately associated with 
DNA. These modifications are under dynamic regulations and subjected to addition and 
removal based on various intracellular and extracellular inputs. The key regulators that 
participate in these modification processes are classified into three groups: writers, 
reader and erasers. Epigenetic writers such as HAT and histone methyltransferases 
(HMTs) catalyze the addition of epigenetic marks on different residues on histone tails; 
readers such as the bromodomains or chromodomain containing proteins bind to these 
epigenetic marks. Epigenetic erasers, as the name implies, facilitate the removal of 
epigenetic marks [132]. These epigenetic marks control the chromatin state and 
represent certain “signatures” for transcription regulator proteins to interpret in order to 





DNA methylation is one of the best characterized chromatin modifications. It 
occurs on at position C5 of the cytidine ring of CpG dinucleotides. Regions of the 
genome where CpG dinucleotides occur at high frequency are called CpG islands, and 
their methylation correlates with transcriptional repression and silenced chromatin state 
[133]. Together with non-coding RNA and histone modifications, DNA methylation plays 
an important role in gene regulation and chromatin organization during development of 
individual organisms and maintenance of tissue homeostasis [134]. 
Histone modifications 
 Histones are subjected to modifications at over 60 different sites, including 
methylation, acetylation and phosphorylation, which primarily cluster on histone N-
terminal tails. These modifications are involved in various chromatin-related processes, 
such as transcription regulation and DNA repair [135]. Especially in the recent years, 
there has been intense interests in determining how different chromatin modifications 
influence the patterns of gene expression. So far, several mechanisms have been 
uncovered. First, some modifications, such as acetylation and phosphorylation, alter the 
electrostatic properties of chromatin fibers, which ultimately lead to remodeling of the 
higher order structure. Second, certain histone modifications can recruit or stabilize the 
localization of chromatin-binding proteins, which further recruit machineries to activate 
or repress gene expression (reviewed in [130]). This understanding led to the proposal 
of the “histone code” theory: the combination of histone modifications forms a readable 
pattern for proteins or protein modules, to bring forth the downstream transcriptional 




commonly associated with transcriptional activation [138, 139], while the effect of 
histone tail methylation is more site-specific [140]. The Hox gene regulation controlled 
by H3K4me3 and H3K27me3 (mentioned in Chapter 1.1.2) is one of the most classic 
examples in this category.  
Additional mechanisms, such as ATP-dependent chromatin remodeling and 
incorporation of histone variants, have also been uncovered. They utilize non-covalent 
modifications to introduce changes to chromatin conformation. For example, ATP-
dependent nucleosome remodeling complexes alter the chromatin accessibility by 
shifting or ejecting nucleosomes, and thus give rise to a regions of relaxed, 
nucleosome-free chromatin for downstream transcription to occur [141]. Together, the 
dynamic interplay among these different mechanisms collectively guides the meaningful 
interpretation of genetic information encoded by the DNA sequences. 
 
1.4.2 Epigenetic regulation in hematopoiesis 
Blood is the most regenerative tissue in adults, with more than one trillion cells 
emerging from bone marrow every day. In this process, named hematopoiesis, HSC 
gives rise to all cellular components in the blood. Like all other cellular differentiation 
processes, hematopoiesis is governed by the dynamic interplay of different epigenetic 
mechanisms. Since it has a well-defined hierarchical pattern from the most primitive 
stem cells to the mature ones (systematically reviewed in [142]), it has served as an 




addition, study of the chromatin regulators in hematopoiesis can also help elucidate 
their dysregulation and identify therapeutic targets in hematological malignancies.   
Lineage-specifying transcription factors 
During hematopoiesis, specific sets of transcription factors must act in a highly 
regulated manner to establish the proper cue for proliferation and differentiation. For 
example, the expression of Gata1 is essential for the erythroid and megakaryocytic 
lineage, and loss of Gata1 converts erythropoiesis to myelopoiesis [143]. For 
myelopoiesis specifically, the differentiation process is orchestrated by a relatively small 
number of transcription factors, including PU.1, CCAAT/enhancer binding proteins - 
C/EBPα, C/EBPβ, C/EBPε, and growth-factor independent 1 (GFI1) [144]. Among them, 
PU.1 and C/EBPα have been shown as the pioneer factors to build the transcriptional 
environment specific for myeloid differentiation [145, 146]. To execute this function, 
these master regulators of each lineage bind to specific DNA sequences, recruit 
transcription co-activators, co-repressors or chromatin-remodelers, and as a result, 
modulate the expression of downstream lineage-specific genes. 
Histone modifications 
 The chromatin modification changes during hematopoiesis were initially 
determined in a locus- and/or modifier-specific manner. For example, it was discovered 
using genetic approaches and targeted ChIP-assays that GATA-1 recruits CBP and 
HAT, leading to the acetylation of H3 and H4 at β-globin locus [147]. Recently, with the 
advancement of low-cell-number ChIP-seq technologies, comprehensive histone 
modification maps have been drawn for the entire hematopoietic hierarchy [148, 149]. 




H3K27me3 – in ESC, partially resolve into either active or repressive domains in HSC, 
and those remaining bivalent domains in HSC can further resolve in mature 
hematopoietic cells [148]. Moreover, formation of novel enhancers also plays a role in 
hematopoiesis. The establishment of de novo enhancers, defined by the emergence of 
H3K4me1 mark, precedes the transcription program changes in differentiation, 
suggesting that the progenitor cells acquire extra regulatory potential before committing 
to a mature cell fate [149]. 
DNA-methylation 
DNA methylation-mediated chromatin silencing is also crucial for hematopoiesis 
and blood tissue homeostasis. For example, Hoxa9 and Meis1, with their important 
functions in HSCs, both possess Differentially Methylated Regions (DMR). These DMRs 
remain unmethylated until the stage of MPPs, then become hypermethylated as 
differentiation proceeds [150]. Loss of the DNA methyltransferase enzymes DNMT1 in 
HSC causes reduced self-renewal and skewed lineage commitment towards the 
myeloid/erythroid lineages [151, 152]. These findings imply that in hematopoiesis, DNA 
methylation-mediated gene silencing and maintenance of the repressive chromatin state 
is as critical as the gene activation process. 
Chromatin accessibility 
Nucleosome eviction at regulatory elements results from binding of specific 
regulatory factors during the establishment of chromatin landscapes [153]. Thus, 
accessible regions of the genome are regarded as the “footprints” of master 




chromatin accessibility, or the “footprint” information, can provide valuable insights on 
the key regulators of a particular cell state [154].  
This methodology has been implemented in the study of hematopoiesis. Lara-
Astiaso et al systematically identified the critical transcription factor cohorts for various 
hematopoietic cell types. They found that the motifs of classical lineage-specifying 
factors, such C/EBPα and PU.1 in myeloid lineage, are overrepresented in their 
respective lineages. According to their discovery, HOXA9 motif is most highly enriched 
in short term-HSC (ST-HSC), multipotent progenitors (MPP) and common lymphoid 
progenitors (CLP), while MEIS1 motif is enriched in long term-HSC (LT-HSC) and ST-
HSC. This result is consistent with their vital role in the stem cell compartment [149]. In 
addition, it is suggested that the chromatin landscape can precisely define a cell identity 
and developmental trajectory. This epigenomic information is also precious to determine 
the developmental context where the disease-related elements become active [155]. 
1.4.3 Epigenetic dysregulation in hematological malignancies 
The advances in genome-wide technologies allow large scale mapping of 
mutations and other genomic events in malignancies. It has been increasingly 
recognized that many hematological malignancies, in particular, are “epigenetic 
diseases” – driven by mutations in chromatin modifiers as well as by genetic alterations 
in the non-coding regions of the genome [156]. As mentioned in 1.3.2, MLL1 
abnormalities constitute a substantial portion of acute leukemia, in both adult and 
pediatric patients. Mutations at tyrosine 641 in the PRC2 complex component EZH2 
occur in ~30% of diffuse large B cell lymphomas [157]. Mutated EZH2 fails to implement 




convert mono- and di-methylated H3K27 into H3K27me3. This mutation thus leads to a 
stoichiometric shift in the H3K27 methylation pattern and inappropriate silencing of 
EZH2 target genes [158]. Thus, abnormalities in epigenetic regulators in cancer result in 
global changes of epigenetic landscapes. 
Mutations and local amplifications of regulatory sequences are also commonly 
identified in hematological neoplasia. Disease-associated Single Nucleotide 
Polymorphisms (SNP) are more enriched in regulatory elements, such as super 
enhancers, than in other regions of the genome [149, 155, 159]. For instance, the 
oncogene Myc is associated with a super enhancer 1.7 Mbp downstream of the gene 
promoter, which is found frequently amplified in leukemia samples [160]. Since mutated 
or dysregulated enhancer elements are frequently found in the proximity of disease-
relevant genes and are critical for their expression, it has been proposed that these  
enhancers confer cell identity and disease phenotypes [159].  
The unique mutational landscape renders the leukemia and lymphoma tissues 
more sensitive to epigenetic treatments than untransformed normal cells. There has 
been an exponential growth in our understanding of the role of epigenetic regulators, as 
well as a swell of interest in targeting them for cancer therapies [161]. For example, 
using CRISPR-Cas9-mediated approaches, Shi et al. found that acute myeloid 
leukemias are dependent on at least 25 epigenetic enzymes out of the 192 chromatin 
modulators in the screening assay [162]. Among them, BRD4, a member of the BET 
(bromodomain and extra terminal domain) family and an acetylated lysine reader, has 
received considerable attention because of the recent success in targeting the BET 




collaborating partner of MLL-fusion proteins [166, 167]. DOT1L is recruited to MLL-
fusion binding sites and mediates transcriptional activation. Its inhibitors have shown 
promising results in targeting MLL-rearrangement leukemias and have entered clinical 
trials [168-170]. These studies together offer great prospects for treating hematological 







HOXA9-mediated epigenetic landscape alterations 
2.1 Introduction 
It has been increasingly recognized that epigenetic dysregulation is one of the 
key characteristics of malignancies [156, 171, 172]. Mutated or misexpressed chromatin 
regulators, such as transcription factors and histone modifiers, trigger the formation of 
an aberrant gene regulation landscape, and thus promote cancer formation [84, 173]. 
Enhancers, the distal regulatory elements of gene expression, are the frequent targets 
of malfunctional regulators, and are re-configured with aberrant histone post-
translational modifications (PTMs) and/or DNA-cytosine hyper- or hypo-methylation. 
Notably, such alterations in enhancer landscape must involve chromatin regions that 
are developmentally silenced; this epigenetic reactivation process is elicited by pioneer 
transcription factors who engage their targets on closed regions and recruit additional 
epigenetic machinery that initiate the relaxation of chromatin. Studies have found a 
subset of transcription factors with this epigenetic remodeling ability during oncogenic 
transformation. It is conceivable that these transcription factors with reprogramming 





It has long been recognized that HOXA9 and its cofactor MEIS1 play a causal 
role in promoting leukemic transformation in both mouse models and human leukemia 
patients. However, the mechanisms through which HOXA9 and its cofactor MEIS1 
directly regulate target genes are poorly understood. Previous studies have shown that 
in a AML cell line, HOXA9 binds on promoter-distal regions whose epigenetic signature 
is indicative of active enhancers. HOXA9 transcriptionally activates a group of 
oncogenes, while represses the myelopoietic pathways and inflammatory responses 
[61]. However, it remains to be fully elucidated how HOXA9 exerts the differential 
regulatory functions, and whether HOXA9 exploits the pre-existing regulatory 
landscape, or remodels it to adopt a leukemogenic cell fate. Here we performed 
coordinated analysis of chromatin states at HOXA9 binding sites in HOXA9/MEIS1-
transformed leukemia cells and their normal hematopoietic counterparts. We discovered 
that HOXA9 reshapes the enhancer landscape and initiates the formation of a group of 
novel enhancers. These de novo enhancers, which likely represent reactivation of an 
embryonic development program, are critical for the oncogenic properties of HOXA9.  
 
2.2 Materials and Methods 
Animals 
All animal experiments were performed as approved by the University of 
Michigan Committee on the Use and Care of Animals and Unit for Laboratory Animal 




mice (JAX no. 000664; The Jackson Laboratory) were purchased and used as 
transplantation recipients. 
Antibodies 
For Western blot analysis, anti-HOXA9 (07-178, Millipore), anti-PTIP and anti-
MLL4 #3 antibodies generated in rabbits were used [175]. For ChIP, anti-HA (ab9110; 
Abcam), anti-C/EBPα (sc-61X; Santa Cruz Biotechnology), anti-MLL4 #3, anti-
H3K4me1 (ab8895; Abcam), anti-H3K27ac (ab4729; Abcam), anti-H3K27me3 (07-449; 
Millipore), and IgG (sc-2027; Santa Cruz Biotechnology) were used.  
For flow cytometry, allopycocyanin (APC) anti-c-Kit (105812; Biolegend), APC 
anti-Gr1 (108412; Biolegend), APC/Cy7 anti-B220 (103224, Biolegend), 
phycoerythrin(PE) anti-CD43 (143205, Biolegend), PE anti-CD11b (101208, Biolegend), 
PE anti-CD16/32 (101307, Biolegend), Peridinin-chlorophyll-Cy5.5 (PerCP-Cy5.5) anti-
CD19 (45-0193-82, eBioscience), PerCP-Cy5.5 anti-Sca1 (45-5981-80), eFluor® 450 
anti-CD34 (48-0341-80, eBioscience) and DAPI (Sigma) were used. 
Cell Lines 
Bone marrow from 6- to 10-week-old C57BL mice was harvested 5 d after 
treatment with 5-flurouracil (150 mg/kg). Lineage-negative (Lin-) bone marrow cells were 
first flushed from femora and tibiae with 25G needles, and then isolated using the 
EasySep Mouse Hematopoietic Progenitor Cell Enrichment Kit (19856, Stem Cell 
Technologies). Lin- cells were maintained in Iscove’s modified Dulbecco’s medium 
(IMDM) supplemented with 15% Fetal Bovine Serum (FBS, Sigma F4135), 10 ng/mL 




To package retroviruses, Plat-E cells (RV-101, Cell Biolabs) were transfected 
with MIGR1-HA-Hoxa9 (Hoxa9) or MIGR1-HA-Hoxa9-estrogen receptor tag (Hoxa9-ER) 
and with MIGR1-Flag-Meis1 (Meis1) retroviral vectors (plasmids previously described in 
[61]) using FuGENE 6 (E2691, Promega). Cell-free supernatant was collected 48 hours 
after transfection.  
To generate the HMM cell line, Lin- BM were spinoculated with Hoxa9 or Hoxa9-
ER and Meis1 retrovirus together at 3200rpm for 90mins at room temperature on two 
consecutive days. Hoxa9-ER/Meis1-transduced cells were then cultured in continuous 
100nM 4-hydroxytamoxifen (OHT) to maintain transformation. After transduction, Lin- or 
Hoxa9(-ER)/Meis1-transduced progenitors were cultured in IMDM with continuous 
10ng/ml IL-3, while SCF was gradually withdrawn in 7 days.  
shRNA knock-down 
To knock-down Aldh1a3, bone marrow from rtTA knock-in mice (no. 006965; The 
Jackson Laboratory) was retrovirally transduced with Hoxa9 and Meis1 to generate HM 
tet-on cells. Aldh1a3 siRNA sequences were cloned into dsRed-expressing TRMPVneo 
vector  [176] and transduced in to HM tet-on cells. Infected cells were then selected with 
1mg/ml G418 (10131, Gibco) for 1 week. Resistant cells were treated with 1μg/ml 
doxycycline to activate the shRNA. RNA samples were taken at 1, 2, 4 and 6 days. 





For HOXA9-inactivation studies, HMM cells were washed three times with culture 
media and then maintained in either 100 nM OHT or equal volume of ethanol for 3 days 
before being used for downstream analysis.  
Competitive proliferation assay was carried out by mixing the parental HM tet-on 
cells with the shRNA-expressing (dsRed+) HM tet-on cells in a 1:3 ratio. The 
percentage of dsRed+ cells was monitored by flow cytometry analysis over the course 
of 10 days. 
For CFU assay, HM tet-on expressing Aldh1a3 shRNA or non-targeting (Renilla) 
shRNA were seeded at 1000 cells/ml in semi-solid methylcellulose-based media 
(Methocult, M3234 STEM CELL Technologies) with 10ng/ml IL-3 and were allowed to 
grow for 6 days. Colonies were stained with iodonitrotetrazolium chloride (I10406, 
Sigma) for 30mins at 37°C, followed by scanning and imaging. 
Cellular morphology was assessed using cytospin followed by HEMA 3 staining 
(22-122-911, Fisher Scientific). Whole-cell lysates were collected by directly lysing 
washed cells in SDS loading buffer plus β-mercaptoethanol. Protein levels were 
visualized using SDS/PAGE and Western blotting on PVDF membranes. RNA was 
collected and purified using a Qiagen RNeasy Kit with on-column DNase treatment. 
cDNA was generated using SuperScript III Reverse Transcriptase (18080093,  
Invitrogen), and target gene expression was determined relative to Gapdh using Power 





For surface marker expression, cells were washed and resuspended in standard 
media (2% FBS and 0.1% NaN3 in DPBS), and incubated for 30 min on ice with 0.2μg 
of the appropriate antibodies. After incubation, cells were washed twice before analysis 
on a Becton Dickinson LSR II. Data collected from at least 20,000 events from biological 
replicate experiments were analyzed using FlowJo Version 10 (TreeStar). 
ChIP 
ChIP assays were conducted as described in [54]. Briefly, cells were fixed for 15 
min at room temperature with 1% paraformaldehyde, lysed in lysis buffer [1% SDS, 10 
mM EDTA, 50mM Tris·HCl (pH 8)] for 10min on ice, and sonicated using Bio-raptor. 
Diluted chromatin was incubated with 2.5μg of appropriate antibody overnight at 4 °C 
with rotation. Immunoprecipitation was then performed using protein G Dynabeads 
(10004D, Thermo Fisher). Immunoprecipitates were washed for 5 min in low-salt (150 
mM), high-salt (500 mM), and lithium chloride (0.25 M) buffers, and twice with 
Tris/EDTA buffer. Captured chromatin was eluted by incubating beads in 250μL of 
elution buffer (1% SDS, 100 mM NaHCO3) for 30 min at 42 °C. Cross-linking was 
reversed by the addition of 50μM NaCl and overnight incubation at 65 °C. Chromatin 
was then RNase A-treated and purified using a Qiagen PCR purification kit. Binding was 
quantified relative to input by quantitative PCR (7500 PCR System; Applied Biosystems) 
using SYBR green fluorescent labeling and primers designed using the Integrated DNA 
Technologies PrimerQuest program. 




The constitutive Cas9 expression construct MSCV-hCas9-PGK-Puro and the 
single guide RNA (sgRNA) expression construct U6-sgRNA-EFS-mCherry were gifts 
kindly provided by Dr. Christopher Vakoc, Cold Spring Harbor Laboratory. All sgRNA 
sequences in this study were designed using https://benchling.com/crispr. The 
sequences with minimal off-target score were chosen. A 5’ guanine (G) nucleotide was 
added to all sgRNA sequences that did not start with a 5’ G, as suggested in [162]. 
To derive constitutive hCas9-expressing HMM cells, HMM cells were 
spinoculated with retrovirus packaged from MSCV-hCas9-PGK-Puro at 3200rpm for 
90mins at room temperature. Transduced cells were selected with 1µg/ml Puromycin, 
and isolated by limiting dilution. Cas9 expression in the monoclonal cell lines were 
tested by Western blotting using CRISPR/Cas9 Monoclonal Antibody [7A9] (A-9000-
050, Epigentek) and two clones with high hCas9 expression were chosen.  
sgRNAs targeting the four Aldh1a3-proximal enhancer regions were designed to 
remove the ATAAA binding motif of HOXA9. To improve the efficiency of enhancer 
deletion, pairs of sgRNAs flanking the same HOXA9 motif were cloned into one U6-
sgRNA-EFS-mCherry vector, by sequentially inserting the two U6-sgRNA cassettes via 
the BsmBI site and the EcoRI/XhoI site. The hCas9-expressing HMM cells were then 
transduced with the sgRNAs-expressing viruses.  At Day 3 post-transduction, mCherry-
expressing cells were individually sorted into 96-well-plates by flow cytometry and were 
expanded into monoclonal cell lines.  
Genomic DNA was isolated from the clonal CRISPR-targeted HMM cell lines 
using Radiant™ Extract & Amplify Tissue PCR kit (C462, Alkali Scientific Inc.). To 




amplified by PCR, with the supposed length of 600-1000bp in wildtype cells. Gel 
electrophoresis was applied to identify the clones with shorter PCR products. The 
sequences of the target regions were confirmed by Sanger DNA sequencing. Aldh1a3 
mRNA expression of the deletion clones was compared with control clones with 
CRISPR-targeted Rosa26 promoter [177]. 
4C-seq 
4C-seq was performed following the protocol published by [178]. Briefly, 1x107 
MP, HMM or HOXA9-inact cells were crosslinked in 1% paraformaldehyde at room 
temperature and lysed in lysis buffer [10mM Tris-CL, pH7.5; 10mM NaCl; 0.2% NP-40; 
1x protease inhibitor (Roche complete mini)] on ice for 10 min. Nuclei were pelleted by 
spinning down at 400g for 5 min, resuspended in 0.5ml 1.2x restriction buffer plus 
0.25% SDS and shaken at 37C for 1h at 900rpm. The nuclei were digested with 400U of 
HindIII (NEB) at 37°C overnight. The restriction enzyme was inactivated by adding 80μl 
10% SDS and incubating at 65°C for 25 min while shaking at 900rpm. Ligation was then 
performed by adding 6.125ml 1.15x ligation buffer, 375μl 20% Triton X-100 and 5μl T4 
DNA ligase and incubating at 16C overnight. Crosslinking was reversed by incubating 
overnight at 65°C with Proteinase K. Chromatin was then RNase A-treated and purified 
using phenol chloroform. Secondary digestion was performed with DpnII, followed by 
heat inactivation of the restriction enzyme and ligation with T4 DNA ligation at 16°C 
overnight. DNA was then purified first by ethanol precipitation and then with Qiagen 
PCR Purification Kit. 100ng chromatin was amplified with Expand Long Template 
Polymerase (ELONG-RO Roche). The primers used to amplify 4C-seq libraries anneal 




sequences of barcode, Illumina adaptor and sequencing primer. Barcoded libraries 
were pooled at equal molar ratio and subjected to massively parallel sequencing using a 
HiSeq 2000 instrument (Illumina) using single-end 50-bp sequencing. 
ChIP-Seq, peak calling and peak annotation 
Multiplexed ChIP-seq libraries were prepared at the University of Michigan DNA 
Sequencing Core. 50-cycle single-end sequencing runs were performed on Illumina 
HiSeq 2500 at a sequencing depth of 10-50 million aligned reads per sample. 
Sequenced reads were preprocessed to trim adaptor sequences (Trimmomatic) and 
then aligned to mouse reference genome (mm9) using BWA software (version 0.6.2). 
Only uniquely mapped reads were used in downstream analyses. Model-based Analysis 
for ChIP-seq (MACS) was used the identification of ChIP-seq peaks with p value=10-4 
for HOXA9. Peaks of C/EBPα and histone modifications were identified with the default 
parameters. Peaks were annotated to their nearby genes using the default parameters 
of GREAT[179]. Genes that associated with both HOXA9+ DE and HOXA9+ PE were 
considered only as DE-regulated genes. Peak overlap was calculated with the criterion 
that there is at least 1bp overlap between the test peaks. Pathway analysis was 
performed using the DAVID Functional Annotation web tool [180]. The HOXA9, 
H3K27me3 and one set of H3K4me1 ChIP-seq data in HMM cells were obtained from 
our previous study [54], the rest were obtained in this study. 
RNA-seq analysis 
Poly-A enriched RNA-seq libraries were prepared at the University of Michigan 




Illumina HiSeq 2500 at a sequencing depth of 40-50 million reads per sample. 
Sequencing reads were aligned to mm9 genome using Tophat (version 2.0.11). 
Transcript counts were generated with HTSeq (version 2.20.1). Differential expression 
analysis was performed with edgeR. 
Global enhancer profile analysis 
The analysis method was slightly modified from [149]. Peaks from 20 H3K4me1 
ChIP-seq samples (MP, HMM, HMB from this study, Pro-B from [138], 16 normal 
hematopoietic cell types from [149]) were combined into one unified catalog. 
Overlapping peaks between replicates (peak center distance < 500bp) were merged, 
and peaks identified in only one replicate were discarded. Any peaks overlapping with 
annotated mouse promoter regions (-2/+1kb of TSS) were removed. Redundant peaks 
that occurred in more than one cell types were reduced to one representative peak with 
the largest fold enrichment within any 2000bp window. This resulted in a catalog with 
116,182 putative peaks. 
We counted H3K4me1 reads within 2kb around peak centers using the 
annotatePeaks.pl function in HOMER suite (http://homer.salk.edu/homer/), normalizing 
to 107 reads per library. Cell types were clustered by hierarchical clustering using the 
log2-transformed counts. Putative peaks in the enhancer catalog were per-peak 
normalized before clustered by K-mean (K=16). Hierarchical clustering and K-means 
clustering were both done using Cluster 3 [181].   




The differential H3K4me1 analysis was performed using DiffBind [182], following 
its reference manual. To consider all normal peaks in the myeloid lineage, MACS 
H3K4me1 peaksets derived from untransformed myeloid CMP, GMP, Monocytes 
(Mono), Macrophages (Mφ), GN and myeloid progenitor (MP) cells were compared with 
peaksets from three replicates of HMM cells ([54] and this study). The dba.count 
function was used with minOverlap=1 and summits=1000. Differential analysis was 
done with DESeq2. Regions with FDR<0.05 were considered as differentially 
methylated. We consider a HOXA9 peak overlapping with a gained or lost H3K4me1 
region if its center is within 2kb from the H3K4me1 summit. 
 
2.3 Results 
2.3.1 HOXA9 binds to active distal regulatory elements in myeloid leukemia cells. 
We previously discovered that the genome-wide binding pattern of HOXA9 in 
HOXA9/MEIS1-transformed myeloid leukemia cells (HMM cells) is consistent with active 
distal regulatory elements [61]. Using the same cell line, we performed chromatin 
immunoprecipitation sequencing (ChIP-seq) to map the global binding of HOXA9, as well 
as histone modifications associated with enhancer status ([54] and this study), and 
confirmed the previous result. Enhancer status is commonly defined with histone post-
translational modifications (PTMs), including histone H3 lysine 4 monomethylation 
(H3K4me1), H3 lysine 27 acetylation (H3K27ac), and H3 lysine 27 trimethylation 
(H3K27me3) signals, so that their status can be classified into primed (H3K4me1 only), 
active (H3K4me1/H3K27ac) or poised (H3K4me1/H3K27me3) [183]. Consistent with our 




but were depleted of H3K27me3, indicating active regulatory potential (Figure 2.1 A). 
When these binding sites were mapped to genomic features, only 6% (n = 405) occurred 
within promoter regions (-2/+1 kb relative to transcription start sites (TSS)). For the 6173 
promoter-distal peaks, the majority (63.5%) overlapped with putative active enhancers 
and 18.1% with the primed regions, while limited binding (1.0%) was found on poised 
enhancers (Figure 2.1 B). 
 
Figure 0-1 HOXA9 binding sites are enriched of active enhancer signature 
 (A) Composite plot showing average per base pair (bp) density of Hoxa9, H3K4me1, 
H3K27ac and H3K27me3 at Hoxa9 binding sites in HMM cells. Library size normalized 
to 1E7 reads. Hoxa9 peaks are enriched with H3K4me1 and H3K27ac globally, but 
depleted of H3K27me3. (B) Percentage distribution among different enhancer states at 
Hoxa9’s promoter-distal binding sites. These sites are preponderantly associated with 
active enhancer signatures. Promoter: -2 ~ +1 kb of transcription start site (TSS). Active 
enhancer: H3K4me1+;H3K27ac+. Primed enhancer: H3K4me1+;H3K27 unmarked. 
Poised enhancer: H3K4me1+;H3K27me3+. Other: H3K4me1 unmarked; H3K27 
unmarked. 
 
2.3.2 HOXA9-mediated transformation reshapes the enhancer landscape in 
myeloid leukemia cells 
Previous studies suggested that distal enhancers are key for maintaining cell type-
specific transcriptome and as a result, cell identity [159, 184]. To test whether HOXA9-




enhancer landscape, we generated a myeloid culture cells (MP cells) under the same in 
vitro culture condition as HMM cells, and used them as the control cell line for HMM cells. 
Both flow cytometric and morphological analysis showed that these two cell types shared 
considerable resemblance, although their transformation status differed (Figure 2.2).  
 
Figure 0-2 The Immunophenotype and histology of MP and HMM cells 
(A) Flow plot showing the surface expression of c-Kit, Sca-1, CD16/32, CD34, CD11b 
and Gr-1 of HMM and MP cells, indicating that they are both mixed populations in the 
myeloid lineage. (B) Cytospin result showing the morphology of HMM cells 4 weeks after 
transformation, and MP cells 1 week in culture. Scale bar: 50µm 
To relate MP and HMM cells to the hematopoietic hierarchy, we conducted 
hierarchical clustering using the H3K4me1 ChIP-seq data from HMM and MP cells, as 
well as from 16 hematopoietic cell types characterized in Lara-Astiaso, D. et al [149]. This 
analysis included LT-HSC and ST-HSC, oligopotent progenitors (CLP, CMP, GMP, MEP), 
as well as terminally differentiated mature cells, such as monocytes (Mono), 
macrophages (Mφ) and B lymphocytes (B). Consistent with the immunophenotypic and 
histological characterization (Figure 2.2), phylogenetic tree based on the global H3K4me1 
dynamic profile revealed that HMM cells were closely related to the cells in myeloid 




origin (Figure 2.3 A). Notably, HMM cells were not only related to MP cells, but instead, 
were classified with the entire myeloid lineage. Therefore, in order to systematically 
examine the gained and lost enhancers specifically for leukemic transformation, we 
performed differential analysis on the H3K4me1 ChIP-seq data from three preparations 
of HMM, as compared with those of all untransformed cells in myeloid lineage (CMP, 
GMP, Mono, Mφ, GN and MP cells).  We identified 11,814 regions that were differentially 
H3K4 monomethylated between HMM and the untransformed cells, among which 3760 
regions consistently gained H3K4me1 density, while 8054 lost intensity (Figure 2.3B, 2.4A 
left panel). Representative loci with gained or lost enhancer(s) are shown in Figure 2.4 C 
(bottom four tracks).  
 
Figure 0-3 The enhancer landscape changes in HMM cells 
 (A) Clustering dendrogram of cell types based on H3K4me1 profiles showing the 
association of HMM cells with the untransformed myeloid cells. (B) Heatmap showing 
the 11,816 differentially enriched H3K4me1 regions between HMM cells and normal 
myeloid cells. Cut-off: FDR < 0.05.  
Interestingly, HOXA9 showed significantly higher occupancy on gained enhancers 




loci (Figure 2.4B). In fact, 20% (n=764) of the gained enhancer were bound by HOXA9; 
in contrast, 1.8% (n=146) of the lost enhancer and 5.8% (n=4558) of the unchanged loci 
overlapped with HOXA9 peaks (Figure 2.4A, right panel), suggesting that the gained 
enhancers are possibly favorable targets of HOXA9. We refer to the gained enhancer 
regions in HMM cells as de novo enhancers (DE), and those that had prior H3K4me1 
modification in the untransformed cells (either lost signal density or remained unchanged) 
as physiological enhancers (PE). Figure 2.4C shows two representative loci with a DE 
and two lost PE, showing that HOXA9 is more likely to occupy DE than PE. 
 
Figure 0-4 HOXA9 binding is enriched at de novo enhancers 
 (A) Pie charts illustrating the percent of enhancers are altered significantly or 
unchanged between HMM and normal myeloid cells (left) and the percent of HOXA9 




density over DE, lost PE and unchanged regions, illustrating that HOXA9 signal is 
significantly enriched at DE. Statistics were obtained from Mann-Whitney U-test. (C) 
UCSC browser views of H3K4me1 profiles from three representative myeloid lineage 
cells -Common Myeloid Progenitor (CMP), Granulocyte (GN), MP cells - and HMM cells, 
illustrating a de novo enhancer (left) and two lost physiological enhancers (right). 
HOXA9 binding at these regions shown on top. Library size normalized to 1E7 reads. 
2.3.3 HOXA9+ DE and HOXA9+ PE have different characteristics 
Given that HOXA9 binds both on the de novo enhancers and on the physiological 
enhancers, we hypothesized that the two types of HOXA9 binding sites would display 
distinct behaviors in leukemic transformation. HOXA9 target sites were then classified 
into two groups based on whether they overlap with de novo enhancers (HOXA9+ DE) or 
physiological enhancers (HOXA9+ PE). As shown in Figure 2.5A, the 4644 HOXA9+ PE 
have the same or reduced H3K4me1 in HMM as compared to MP cells, while the 764 
HOXA9+ DE have H3K4me1 only in HMM cells.  Consistent with the fact that MP cells 
were a mixture of cells at different stages of myeloid differentiation, HOXA9+ PEs were 
also H3K4 monomethylated at various level in normal myeloid lineage cells, suggesting 
that they have potential functions in hematopoiesis (Figure 2.5B, lower panel). In contrast, 
HOXA9+ DE were exclusively enriched in transformed HMM cells, but were not identified 
in any hematopoietic cell types. Notably, the modification at these regions was unlikely 
remnants of cis-regulatory elements in early hematopoiesis, as they were not present in 
the undifferentiated progenitors (LT-HSC, ST-HSC and MPP) (Figure 2.5B, upper panel). 
The majority of HOXA9+ PE in both MP and HMM cells, as well as HOXA9+ DE in HMM 
cells, were active enhancers with high H3K27ac. Furthermore, no H3K27ac was found at 






Figure 0-5 HOXA9+ DE are specifically active in HOXA9-dependent AML cells 
 (A) Heatmap depicting the corresponding signal intensity of HOXA9 in HMM cells and 
H3K4me1 in MP, HMM and MLLAF9 cells at 5,407 HOXA9-bound distal regulatory 
elements (HOXA9+ PE and DE). The rows show 3kb upstream and downstream of 
HOXA9 peak center. Peaks sorted based the total normalized H3K4me1 tag counts 
within each category. (B) Heatmap depicting signal intensity of H3K4me1 and H3K27ac 
at 788 HOXA9+ DE and 4643 HOXA9+ PE in normal hematopoietic cells of different 
differentiation stages into the myeloid lineage. (C) Heatmap depicting the corresponding 




UCSC browser view of HOXA9, H3K4me1 and H3K27ac profile before and after 
HOXA9-mediated transformation at HOXA9+ DE in Igf1 (left) and Pde11a (right) intronic 
regions. 
To further confirm the functional relevance of HOXA9-mediated DE in 
leukemogenesis, we examined H3K4me1 at HOXA9+ PE and DE in MLL-AF9 leukemia 
cells, which are driven by MLL-AF9 fusion proteins and aberrantly over express HOXA9 
[112]. As shown in Figure 2.5A and C, both H3K4me1 and H3K27ac distribution patterns 
at HOXA9-bound enhancers were strikingly similar to that of HMM cells. The lower 
H3K4me1 at DE in MLL-AF9 cells was probably due to relatively low HOXA9 level in 
these cells as compared to HMM cells (data not shown). These results suggest that 
establishment of DE is a fundamental mechanism of transformation by HOXA9.  
2.3.4 DE and PE have different dependency on HOXA9 
To establish the causal relationship between HOXA9 and the establishment of DE 
in HOXA9/MEIS1-driven leukemia, we employed the inducible form of HMM cells. In this 
cell line, HOXA9 is constitutively overexpressed but activated only in the presence of 
tamoxifen (OHT). As a result, OHT withdrawal causes HOXA9 inactivation and cellular 
differentiation [61]. Importantly, we observed significant reduction of H3K4me1 at 
HOXA9+ DE 72 hours after HOXA9 inactivation (Figure 2.6A, right panel, p=2.40E-14). 
On the contrary, H3K4me1 slightly increased at HOXA9+ PE after HOXA9 inactivation 
(Figure 2.6A, left panel, p=8.02E-5). Distinct and reversible requirement of HOXA9 for 
H3K4me1 at DE, as compared to PE, prompted us to examine the binding of other 
transcription factors at these genomic loci. Previous studies show that C/EBPα mediates 
the creation of myeloid specific enhancers [145, 146, 185] and functionally collaborates 




DE and PE, we performed ChIP-seq analyses for C/EBPα in HMM cells with or without 
HOXA9 inactivation. ChIP-seq in the untransformed MP cells were used as the control. 
As shown in Figure 2.6B, C/EBPα bound at relatively high level at HOXA9+ PE in both 
MP and HMM cells regardless of the transformation status. In accordance, its binding at 
PE was not significantly affected by HOXA9 inactivation. This is foreseeable as C/EBPα 
occupies a large subset of enhancers in lineage-committed myeloid cells [185]. 
Interestingly, C/EBPα binding at HOXA9+ DE was completely dependent on HOXA9: 
C/EBPα bound at an extremely low level at DE in MP cells and significantly increased 
upon HOXA9 over expression and leukemic transformation. Furthermore, C/EBPα 
binding at DE was drastically reduced upon HOXA9 inactivation (Figure 2.6B, right panel). 
Figure 2.6C shows two representative genes, Ikzf2 and Crhbp, regulated by HOXA9+ DE 
with both increased H3K4me1 and C/EBPα binding upon transformation.  Together, these 
results suggest that HOXA9 has distinct functions at two classes of enhancers: 1) at DE, 
it acts as a pioneer transcription factor to recruit other transcription factor(s) and mediate 
the incorporation of enhancers marks in leukemia cells; and 2) at PE, it exhibits 
opportunistic binding and is dispensable for the formation and maintenance of these 





Figure 0-6 HOXA9 is essential for H3K4me1 maintenance and C/EBPα binding at DE 
 (A) Composite plots showing the change of average H3K4me1 signal at HOXA9+ PE 
and DE in HMM and in HOXA9-inactivated HMM cells (HOXA9-inact). Statistics obtained 
by K-S test (B) Composite plots showing the change of average C/EBPα signal at 
HOXA9+ PE and DE in MP, HMM and HOXA9-inact cells. (C) UCSC browser view of 
HOXA9, H3K4me1 and C/EBPα profile before and after HOXA9-mediated transformation 
at HOXA9+ DE at Igf1 (left) and Pde11a (right) intronic regions. 
2.3.5 HOXA9 ectopically activates developmental programs with de novo 
enhancers 
To evaluate whether the two classes of HOXA9-bound enhancers exert differential 
functions, we performed Gene Ontology (GO) analyses on the associated genes. This 
showed that while PE and DE were equally enriched for several common pathways such 
as regulation of metabolic processes and cell signaling, they diverged significantly for 




developmental pathways for HOXA9-bound DE (Figure 2.7A). This result was consistent 
with reactivation of the embryonic gene program in MLL rearranged leukemia [187] as 
well as the critical roles of Hox genes in early development [188]. RNA-seq analyses for 
MP and HMM cells showed that genes associated with DE were significantly upregulated 
in HMM cells as compared to MP cells (Figure 2.7B), and this upregulation was mitigated 
72 hours after HOXA9 inactivation (HOXA9-inact). In contrast, expression of genes 
associated with PE had no significant differences among MP, HMM and HOXA9-inact 
cells. The strong association of DE, but not PE, with embryonic gene programs, as well 
as prominent up regulation of DE regulated genes in HMM cells, suggests that the HOXA+ 






Figure 0-7 HOXA9 activates embryonic development and organogenesis pathways with 





 (A) Gene Ontology Biological Processes for HOXA9+ PE and DE-associated genes with 
the corresponding Benjamini p-values. Pathways specifically enriched with DE are 
highlighted. (B) Transcriptional activity (RPKM) of PE and DE-associated genes in MP, 
HMM and HOXA9-inact cells, respectively. P-values are obtained from Mann-Whitney U-
test. (C) Transcriptional changes in genes associated with DE and PE are shown in the 
scatter plots. The log2 fold change in HMM vs. MP is plotted on the x axis, and log2 fold 
change in HOXA9-inact vs HMM on the y-axis. Upper panel: DE-associated genes. Lower 
panel: PE-associated genes. Blue: x> log2(1.5) = 0.585 and y < -log2(1.2) = -0.263. Red: 
x < -log2(1.5) = -0.585 and y < -log2(1.2) = -0.263. I: DE-associated HOXA9 activated 
genes. II: DE-associated HOXA9 repressed genes. III: PE-associated HOXA9 activated 
genes. IV: PE-associated HOXA9 repressed genes. (D) Gene Ontology Biological 
Process terms associated with the Class I, II, III and IV genes. Pathways specifically 
enriched with I are highlighted. (E) Heatmap showing the normalized read counts of 
H3K4me1 at enhancers and RPKM of representative genes in Class I and Class IV.  If 
multiple HOXA9+ enhancers are found, the one nearest to gene promoter was selected. 
As shown in Figure 2.7C, for both HOXA9+ DE and PE, most genes upregulated 
by HOXA9/MEIS1-mediated transformation were down-regulated by HOXA9 inactivation 
(HOXA9-activated targets). Genes down-regulated by the transformation were more likely 
to be up-regulated by HOXA9 inactivation (HOXA9-repressed targets). This reversion in 
the transcriptome is consistent with the finding that HOXA9 inactivation leads to an exit 
of the leukemogenic status in HMM cells, as well as partial myeloid differentiation [61]. 
Based on this result, we classified HOXA9+ DE- and PE-associated genes in to four 
subgroups based on their responses to HOXA9. For DE, more genes were activated by 
HOXA9 than repressed (Group I: 226 vs. Group II: 108); for PE, fewer genes were 
activated by HOXA9 than repressed (Group III: 462 vs. Group IV: 565). This distinction in 
transcription changes between DE and PE is consistent with the change in H3K4me1. 
Furthermore, when GO analysis was performed on the four groups of genes, we found 
that multiple organogenesis pathways were specifically enriched with Group I genes, 
while immune and apoptotic responses were enriched with Group II and IV (Figure 2.7D). 
Representative genes from group I as well as group II/IV were shown in Figure 2.7E. 




establishing a new epigenomic landscape in support of a primitive/embryonic 
transcriptome. Notably, several genes previously implicated in hematological 
malignancies (e.g Igf-1 [114, 115], Bcl-2 [189, 190], and Erg [73, 113] ) were identified as 
direct HOXA9 downstream targets, further supporting the central role of HOXA9 in 
leukemic transformation. 
2.3.6 HOXA9 regulates Aldh1a3 expression with de novo enhancers 
The gene that showed strongest activation with HOXA9+ DE is Aldh1a3, a key 
component of the retinoic acid metabolism pathway [191] and a therapeutic target in solid 
tumors [192-195]. We used Aldh1a3 as a model to examine long distance gene regulation 
by HOXA9-dependent de novo enhancers. As shown in Figure 2.8A, Aldh1a3 expression 
was significantly upregulated in HMM cells and downregulated upon HOXA9 inactivation. 
To examine the functional requirement of Aldh1a3 in HMM cells, we employed an 
inducible knock-down system to specifically target its expression. Decreased expression 
of Aldh1a3 led to reduced cell proliferation (Figure 2.8B) and colony formation on 
methylcellulose (Figure 2.8C), suggesting a critical role of this gene for the survival and 





Figure 0-8 Loss of Aldh1a3 impairs cell proliferation and colony formation 
 (A) Bar plot showing the normalized expression level of Aldh1a3 in MP, HMM and 
HOXA9-inact. Transcription level of Aldh1a3 in MP cells was set as 1. (B) Percentage of 
shRNA positive cells in the 10-day course after the induction of Aldh1a3 shRNA or non-
targeting Renilla shRNA. shRNA-expressing cells are 3:1 mixed with parental cells at 
Day 0, and their percentage constitution was monitored with flow cytometry. (C) CFU-
assay in Methylcellulose showing the reduction of colony-forming units after Aldh1a3 
knockdown. 
We identified three HOXA9+ DE upstream of Aldh1a3 gene promoter at -53kb, -
77kb and -118kb respectively.  All three DEs were highly enriched for the active enhancer 
signatures, H3K4me1 and H3K27ac, in HMM cells (Figure 2.9A). Notably, several 
chromatin regions near the Aldh1a3 promoter also had HOXA9-dependent H3K4me1 up 
regulation during leukemic transformation but had little or no direct HOXA9 binding 
(Figure 2.9A, regions 1). Interestingly, region 1, which was indirectly regulated by HOXA9, 




enhancers play a causal role in regulation of Aldh1a3 expression, we first performed 
Circular Chromatin Conformation Capture with High-throughput Sequencing (4C-seq) in 
MP, HMM and HMM cells with HOXA9 inactivation. With Aldh1a3 TSS as the view point, 
we found that regions 1, 2, and 4 had significant long-distance interactions with the TSS 
(Figure 2.9B, top panel). These interactions were HOXA9-dependent since HOXA9 
inactivation reduced their interaction frequency (Figure 2.9B, bottom panel), indicating 
that HOXA9 is required for the effective looping of region 1, 2 and 4 to Aldh1a3 promoter. 
In contrast, region 3 showed no interaction with Aldh1a3 TSS in any cell line, suggesting 
that it is not a distal regulatory enhancer for this gene. We next used CRISPR/Cas9-
mediated genome editing to delete each of regions 1 to 4 in HMM cells. We also targeted 
the Rosa26 promoter with the same CRISPR strategy and used it as a negative control. 
After confirmation of specific deletion of the genomic regions (Supplemental Figure 6B), 
we examined Aldh1a3 expression by qRT-PCR.  As shown in Figure 5F, deletion of 
regions 2 and 4 completely abolished Aldh1a3 expression, suggesting that they play non-
redundant functions in Aldh1a3 regulation. Interestingly, deletion of region 1, which was 
not bound by HOXA9, only modestly affected Aldh1a3 expression. Together, these 
results strongly support that HOXA9 plays a direct and causal role in promoting long-
distance interactions between distal regulatory enhancers and gene promoters, which is 





Figure 0-9 HOXA9 regulates Aldh1a3 expression via two HOXA9+ DE 
 (A) ChIP-seq binding profile of HOXA9, H3K4me1 and H3K27ac around Aldh1a3 TSS 
and 150Mbp upstream region. Library size normalized to 1E7 reads. Three HOXA9+ DE 
annotated with Aldh1a3 TSS (2, 3 and 4) as well as a no-HOXA9 enhancer region (1) 
are shaded in grey. (B) 4C-seq analysis showing the interaction frequencies between 
Aldh1a3 TSS and the four enhancer regions of interest. Library size normalized to 1E7 
reads. (C) qRT-PCR analysis of relative Aldh1a3 expression after CRISPR-mediated 
deletion of enhancer 1, 2, 3 and 4. Transcription level of Aldh1a3 in the Rosa26-
targeting cells was set as 1. 
 
2.4 Discussion 
In this Chapter, we systematically characterized the genome-wide enhancer state 
alterations in HOXA9/MEIS1-transformed AML cells, and discovered that the leukemic 




factors, HOXA9 mediates the formation of de novo enhancers, which are in turn 
required for the activation of the specific transcription program in leukemia. 
2.4.1 The pioneer role of HOXA9 in the creation of de novo enhancers 
It has been previously reported that HOXA9 binding sites are enriched for active 
enhancer modifications in leukemia cells [61]. However, it was unclear whether HOXA9 
passively binds on pre-accessible enhancer regions or targets inactive chromatin to 
induces the establishment of novel enhancers during the transformation process. Since 
HOX proteins all recognize a very similar set of ‘‘AT’’-rich sequence motifs, which seem 
to be insufficient for its precise instructive role in vivo [41], their binding is considered 
highly  dependent on DNA accessibility and collaborator proteins. Several co-binding 
partners of HOXA9 have been identified as pioneer factors in different cellular contexts, 
such as PBX1 in breast cancer [196] and C/EBPa in myelopoiesis [145]. Based on our 
current findings, we argue that HOXA9 also acts as a pioneer factor at specific loci, 
when it is pathologically overexpressed. While a large fraction of HOXA9 binds on pre-
established enhancers and is dispensable for the H3K4me1 implementation at those 
sites, a subset of HOXA9 travels to novel regions with no prior H3K4me1 and directly 
mediates the creation of active enhancers. Induction of these sites is achieved despite 
the lack of enhancer formation in MP cells, its putative cell-of-origin, or any other 
progenitor and mature cells in hematopoiesis. At these loci, it recruits, instead of being 
recruited by, C/EBPa and mediates H3K4 monomethylation. HOXA9’s pioneer binding 
is demonstrated as vital for the stable assembly of transcriptional machinery such as 




HOXA9 on its own is unlikely sufficient to remodel chromatin and recruit 
methyltransferase and acetyltransferase; it likely plays this role in concert with its 
transcription cofactors, such as MEIS1 and PBX1, since co-over expression with MEIS1 
is required for its leukemogenesis. Multimeric complex assembly is likely essential for 
the complete transition from closed to open chromatin configuration. To fully 
characterize the pioneer role of HOXA9, chromatin accessibility changes upon HOXA9 
activation and the percent of HOXA9 targeting inaccessible regions need to be 
evaluated. 
2.4.2 The functions of de novo enhancers 
The genes activated by HOXA9+ de novo enhancers are specifically enriched for 
tissue morphogenesis and multiple organ developmental pathways. Similar activation of 
embryonic program has also been found in HOXA9-dependent MLL-AF9 leukemia. This 
is consistent with Hox genes’ role in specifying cell fate and controlling organogenesis in 
early development [7], and that misexpression of Hox genes causes homeotic 
transformation [4, 5]. In neoplasia, abnormal expression of Hox genes leads to 
differentiation failure, altered characteristics and adoption of an alternative cell fate 
[197]. In this model, over expression of Hoxa9 ectopically activates the transcriptional 
program underlying a different cell fate, such as the development of vasculature system, 
while suppresses hematopoiesis fate in the bone marrow progenitors. Thus, the de 
novo enhancers in HOXA9-mediated leukemias are likely to bear regulatory functions in 
other developmental lineages. Indeed, 80% of the HOXA9+ de novo enhancers are 
identified with H3K4 monomethylation in at least one normal tissue type curated in the 




abnormally acquire characteristics of other lineages and 2) de novo regions possess 
regulatory potential in other lineage contexts or developmental stages. With the 
exception of Aldh1a3 enhancers tested here, the exact function of each individual 
HOXA9+ de novo enhancer in both development and leukemogenic transformation 







The MLL3/MLL4 complex collaborates with HOXA9 to 
promote the development of leukemia 
3.1 Introduction 
 Histone modifications, such as methylation and acetylation, constitute one of the 
most critical players in the regulation of gene expression. The monomethylated histone 
H3 lysine 4 (H3K4me1) broadly marks multiple classes of enhancer regions, which are 
further demarcated by the modifications on H3 lysine 27 into active, primed and poised 
subtypes. Genome-wide aberrations of H3K4me1 have been noted in several types of 
malignancies [198-201], which are linked to the specific transcriptional programs in 
oncogenic transformation. 
 Histone-lysine N-methyltransferase (KMT2) family proteins catalyze the addition 
of methyl group(s) on lysine 4 of the histone H3 tail. They are also named MLL family 
proteins, because their founding member KMT2A (MLL1) was first identified undergoing 
genetic rearrangement in mixed-lineage leukemia. For the sake of consistency, here I 
use the old nomenclature, mouse MLL1-4 or human MLL1,4,3,2, to refer to KMT2 A-D. 
The SET domain of MLL family members have histone methyltransferase activity. 
Although their substrate specificity is still being investigated, a multitude of studies have 




and MLL2 are capable of mediating H3K4 mono-, di- and tri-methylation [202].  MLL 
proteins act in large complexes composed of both common and specific subunits. The 
four subunits common to all MLL complexes are WD repeat protein 5 (WDR5), 
Set1/Ash2 histone methyltransferase complex subunit ASH2 (ASH2L), retinoblastoma-
binding protein 5 (RBBP5) and DPY30 [203]. Specific subunits, such as menin in the 
MLL1/MLL2 complex and the PTIP in the MLL3/MLL4 complex, are employed to target 
these complexes to certain genomic loci [204]. 
 Not only are MLL family proteins frequently mutated in human solid and blood 
cancer, their wild type form has also been implicated in the epigenetic dysregulations 
underlying several types of hematological neoplasia. The role of MLL proteins in 
tumorigenesis seems to be complex and context-dependent, since genetic alterations 
resulting in loss of the protein function are able to both accelerate and repress 
oncogenic transformation. This dual role can be well illustrated with MLL4 (KMT2D). In 
diffuse large B cell lymphoma, its genetic ablation or loss of function mutations promote 
lymphoma development, and it thus serves as a tumor suppressor, in both mice and in 
human patients [201, 205]. However, in the MLL-AF9-driven acute myeloid leukemia 
model, MLL4 is required for the maintenance of cancer stem cell properties and the 
rapid onset of leukemia in mice [206]. Moreover, specific targeting of the SET domain of 
MLL4 impairs the proliferation of MLL-AF9-transformed cells, indicating that the 
methyltransferase activity of MLL4 is indispensable for this type of leukemia [162]. By 
contrast, SET-domain deletion in MLL1 fails to inhibit MLL-AF9-induced leukemia 
initiation [207], suggesting that members of MLL family may be differentially utilized in 




 In the previous chapter, I systematically assessed the leukemic enhancer 
landscape changes induced by HOXA9 over expression. I found that the leukemia-
specific, de novo enhancers drive a leukemia-specific transcription program and are 
most responsive to HOXA9 over expression and inactivation. Subsequently, I set out to 
explore the mechanisms by which the de novo enhancers are established, and identify 
a collaborating chromatin regulating complex. As HOXA9 itself is difficult to target 
therapeutically, determining the collaborating epigenetic modulators may provide further 
mechanistic insights for development of epigenetic therapy for acute myeloid leukemia. 
3.2 Materials and Methods 
Mice 
For Ptip or MLL4 SET domain deletion in vitro and in vivo assays, C57BL/6 mice 
(WT), Ptip f/f [208] or Mll4-SETf/f (Kai Ge lab, unpublished) mice were crossed with 
B6.129-Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J mice (JAX no. 008463; The Jackson Laboratory) 
to obtain Ptip f/f;CRE-ER +/-, Mll4-SETf/f; CRE-ER+/- or WT;CRE-ER +/- mice.  
Antibodies 
For Western blot analysis, anti-HOXA9 (07-178, Millipore), rabbit anti-PTIP and 
anti-MLL4 #3 antibody were used [175]. For ChIP, anti-HA (ab9110; Abcam), anti-MLL4 
#3, anti-H3K4me1 (ab8895; Abcam), and IgG (sc-2027; Santa Cruz Biotechnology) 
were used. For flow cytometry, allopycocyanin (APC) anti-Gr1 (108412; Biolegend), PE 






Bone marrow from 6- to 10-week-old Ptip f/f ;CRE-, Ptip f/f; Cre-ER+/−, WT;Cre-
ER+/−, mice was harvested 5 d after treatment with 5-flurouracil (150 mg/kg). Lineage-
negative bone marrow cells were first flushed from femora and tibiae with 25G needles, 
and then isolated using the EasySep Mouse Hematopoietic Progenitor Cell Enrichment 
Kit (19856, Stem Cell Technologies). Lin- cells were maintained in Iscove’s modified 
Dulbecco’s medium (IMDM) supplemented with 15% Fetal Bovine Serum (FBS, Sigma 
F4135), 10 ng/mL Interleukin (IL) -3, and 100 ng/mL stem cell factor (SCF).  
To package retroviruses, Plat-E cells (RV-101, Cell Biolabs) were transfected 
with MIGR1-HA-Hoxa9 or with MIGR1-Flag-Meis1 retroviral vectors [plasmids 
previously described by [61]] using FuGENE 6 (E2691, Promega). Cell-free supernatant 
was collected 48 hours after transfection. To overexpress Hoxa9 and Meis1, Lin- BM 
were spinoculated with Hoxa9 and Meis1 retrovirus together at 3200rpm for 90mins at 
room temperature on two consecutive days.  
Immunoprecipitation 
HMM or MLLAF9 cells were washed with DPBS and lysed in M-PER regent 
(78501, Thermo Fisher) supplemented with 10µl/ml Halt Protease Inhibitor Cocktail 
(87786, ThermoFisher) and 10µl/ml Halt Phosphatase Inhibitor Cocktail (78428, 
ThermoFisher) at 4°C for 30mins. Nuclear extracts were pelleted and treated with 
500U/ml Benzonase Nuclease (07664, Millipore) at 4°C for 30mins. Nuclease activity 
was terminated with 5mM EDTA. After the debris was pelleted at 4°C for 30mins at 
14,000g, the supernatant was pre-cleared with rat IgG-AC (sc-2344, Santa Cruz) at 4°C 




overnight with rotation. The beads were washed twice each with M-PER reagent 
containing zero, 150mM and 300mM NaCl. The beads were eluted by heat denaturation 
at 95°C for 5mins. The protein contents were examined by western blotting. 
Flow Cytometry 
For surface marker expression, cells were washed and resuspended in standard 
media (2% FBS and 0.1% NaN3 in DPBS), and incubated for 30 min on ice with 0.2μg 
of the appropriate antibodies. After incubation, cells were washed twice before analyzed 
on a Becton Dickinson LSR II. Data collected from at least 20,000 events from biological 
replicate experiments were analyzed using FlowJo Version 10 (TreeStar). 
in vivo leukemogenesis assay 
To induce Ptip deletion prior to transplantation, Hoxa9/Meis1-transformed 
Ptipf/f;Cre-ER+/− cells were treated continuously with 5 nM tamoxifen (OHT, H7904; 
Sigma) to generate Ptip-/- cells. Then Ptip-/- or Ptipf/f cells (no CRE) were injected via tail 
vein in cohorts of lethally irradiated (900rad) 8-week-old female mice (1.25×105 cells per 
mouse). To induce Ptip deletion after engraftment, WT;CreER+/- cells or Ptipf/f;Cre-ER+/− 
were directly injected into irradiated C57BL/6 female recipient mice. Mice in all groups 
were maintained on antibiotics for 2 weeks post-irradiation. After 14 days, mice were 
treated with intraperitoneal injections of OHT (200 mg/kg) twice a week until becoming 
moribund. Moribund mice were euthanized. Liver, spleen, heart and bone were 
harvested from control and leukemic mice at the time of death for paraffin embedding 




and cytospin samples. Survival curves were plotted in Prism (GraphPad), and statistical 
significance was evaluated by log rank test.  
ChIP 
ChIP assays were conducted as described in [54]. Briefly, cells were fixed for 15 
min at room temperature with 1% paraformaldehyde, lysed in lysis buffer [1% SDS, 10 
mM EDTA, 50mM Tris·HCl (pH 8)] for 10min on ice, and sonicated for 15 min twice 
using Bio-raptor. Diluted chromatin was incubated with 2.5μg of appropriate antibody 
overnight at 4 °C with rotation. Immunoprecipitation was then performed using protein G 
Dynabeads (10004D, Thermo Fisher). Immunoprecipitates were washed for 5 min in 
low-salt (150 mM), high-salt (500 mM), and lithium chloride (0.25 M) buffers, and twice 
with Tris/EDTA buffer. Captured chromatin was eluted by incubating beads in 250μL of 
elution buffer (1% SDS, 100 mM NaHCO3) for 30 min at 42 °C. Cross-linking was 
reversed by the addition of 50μM NaCl and overnight incubation at 65 °C. Chromatin 
was then RNase A-treated and purified using a Qiagen PCR purification kit. Binding was 
quantified relative to input by quantitative PCR (7500 PCR System; Applied Biosystems) 
using SYBR green fluorescent labeling and primers designed using the Integrated DNA 
Technologies PrimerQuest program. 
ChIP-Seq, peak calling and density calculation 
Multiplexed ChIP-seq libraries were prepared at the University of Michigan DNA 
Sequencing Core. 50-cycle single-end sequencing runs were performed on Illumina 
HiSeq 2500 at a sequencing depth of 10-50 million aligned reads per sample. 




then aligned to mouse reference genome (mm9) using BWA software (version 0.6.2). 
Only uniquely mapped reads were used in downstream analyses. Model-based Analysis 
for ChIP-seq (MACS) was used the identification of ChIP-seq peaks with p value=10-4 
for MLL3/MLL4. Peaks of histone modifications were identified with the default 
parameters. For composite plots, we counted the per bp tag density within 6kb around 
peak centers using the annotatePeaks.pl function in HOMER suite 
(http://homer.salk.edu/homer/), normalizing to 1E7 reads per library. 
 
3.3 Results 
3.3.1 HOXA9 recruits H3K4 methyltransferase MLL3/MLL4 to the de novo 
enhancer sites. 
The ability of HOXA9 to establish active enhancer signatures at de novo binding 
sites raised the question of which histone modifying enzymes are responsible for HOXA9-
dependent chromatin changes. Although previous studies have shown that HOXA9 is 
able to recruit histone acetyltransferase p300 via its cofactor MEIS1 [62], it remains 
unclear which H3K4 methyltransferase is required for HOXA9-mediated enhancer 
modification. Among the six MLL family H3K4 methyltransferases in mammals, MLL1, 
MLL3 and MLL4 are able to deposit H3K4me1 at distal enhancers [202]. Furthermore, 
our previous studies showed that inhibiting MLL1 methyltransferase activity had minimal 
effects on HOXA9/MEIS1 leukemia [89]. Based on these results, we posited that HOXA9 
functions through the MLL3/MLL4 complex to establish H3K4me1 enhancer signature in 
HMM cells. Indeed, when we immunoprecipitated HA-HOXA9 from HMM cells, both MLL3 




This interaction was specific, since neither MLL3/MLL4 nor PTIP was detected from HA-
IP using control MLL-AF9 cells (Figure 3.1A).  
 
Figure 0-1 MLL3/MLL4 binds active enhancers and co-purifies with HOXA9. 
 (A) Co-immunoprecipitations performed with anti-HA antibody in HMM cells. 
Immunoblots show that PTIP and MLL3/MLL4 both immunoprecipitate with HOXA9. 
HOXA9 is HA-tagged in HMM cells, but is untagged in MA9 cells. (B) The genomic 
distribution of MLL3/MLL4 peaks 
To confirm that the MLL3/MLL4 complex functions in conjunction of HOXA9/MEIS1 
in HMM cells, we performed ChIP-seq for MLL3/MLL4 using a previously characterized 
antibody [209], which recognizes both MLL3 and MLL4 proteins (Kai Ge, unpublished 
data). Consistent with previous studies [210, 211], the majority of MLL3/MLL4 chromatin 
binding was at active enhancers in HMM cells (Figure 3.1B). Strikingly, a significant 
portion (39%) of MLL3/MLL4 peaks overlapped with those of HOXA9 (Figure 3.2A). 
Representative ChIP-seq signals for HOXA9 and MLL3/MLL4 are shown in Figure 3.2B. 
Co-localization of HOXA9 and MLL3/MLL4 was further validated by quantitative ChIP-
qPCR (Figure 3.2C and D, black bars). To confirm that MLL3/MLL4 functions downstream 
of HOXA9 in enhancer regulation, we performed MLL3/MLL4 ChIP-seq in HMM cells after 
HOXA9 inactivation. Interestingly, we found that while MLL3/MLL4 binding were not 




HOXA9 inactivation. This distinction is shown at selected HOXA9+ DE and PE loci (Figure 
3.2 D). Regions 1-4 were examined for Aldh1a3 regulation activity in Chapter 2.3.6. 
Among them, regions 2 and 4 were confirmed to be HOXA9-dependent de novo 
enhancers that are required for Aldh1a3 upregulation in HMM cells. Interestingly, these 
loci had reduced MLL3/MLL4 binding after HOXA9 inactivation (Figure 3.2 D, red arrows). 
By contrast, the same treatment had no impact on selected HOXA9+ PE loci (Figure 3.2 
D, black box), although HOXA9 binding significantly decreased (Figure 3.2 C, black box). 
Given that MLL3/MLL4 are considered responsible for implementing the H3K4me1 mark 
at enhancers, this observation is consistent with the finding in Chapter 2.3.4 that HOXA9 
inactivation specifically reduces H3K4me1 at the de novo enhancers. Collectively, these 
results suggest that HOXA9 physically interacts with MLL3/MLL4, and is essential for 





Figure 0-2 HOXA9 colocalizes with the MLL3/MLL4 histone methyltransferase complex, 
and is required for its binding on de novo enhancers 
 (A) Venn diagram showing the ChIP-seq peak physical overlap between HOXA9 and 
MLL3/MLL4. Overlap criteria set to be 1bp. (B) Representative plots showing the co-
localization of HOXA9 and MLL3/MLL4 at HOXA9+ DE across the Aldh1a3 and Spred2 
loci. (C-D) Quantitative ChIP assay of HOXA9 and MLL3/MLL4 at Adh1a3-proximal 
regulatory regions 1-4, as well as HOXA9+ PE loci genes (black box), validating 
MLL3/MLL4’s dependency on HOXA9 at DE. Red arrows indicate significant reduction 
of MLL3/4 binding signal. (E-F) Composite plots depicting the per bp average 




3.3.2 Disruption of the MLL3/MLL4 complex impairs HOXA9/MEIS1-mediated 
leukemogenesis  
Given that HOXA9 physically interacts with MLL3/MLL4, we next examined if 
MLL3/MLL4 was required for HOXA9/MEIS1-mediated leukemogenesis. To this end, we 
used the conditional Ptipf/f; CRE-ER mouse model, in which Ptip can be conditionally 
deleted by OHT treatment. PTIP is a core component of the MLL3/MLL4 complex and is 
essential for MLL3/MLL4 chromatin binding and activity [175, 209, 212]. We first 
transduced Ptip f/f or Ptip -/- Lin- BM cells with Hoxa9/Meis1 viruses, and then transplanted 
them into lethally irradiated recipient mice. All mice (n=8) transplanted with Ptip f/f cells 
developed severe symptoms of leukemia within 38 days, including weight loss, shortness 
of breath, splenomegaly (Figure 3.3B), heart and liver infiltration (Figure 3.3C), and had 
high blast percentage in circulation (Figure 3.3C). In contrast, mice transplanted with Ptip 
-/- cells had a significant delay in disease onset and did not succumb to leukemia until 
after 60 days (Figure 3.3A). Extension of the leukemia latency was also observed even 
when Ptip was excised two weeks after cells were transplanted into syngeneic recipient 
mice (Figure 3.3D), suggesting that the delayed disease onset was not due to impaired 
homing or engraftment. Importantly, genotyping results showed that leukemia cells 
isolated from these mice still had intact Ptip f/f alleles; indicating that they were escapees 
from CRE-ER-induced Ptip deletion (data not shown). Re-expression of Ptip in the 
leukemia cells was also confirmed by RT-qPCR and immunoblot (Figure 3.4A), which 
suggests that the few clones that escaped the deletion treatment had higher survival 





Figure 0-3 Loss of Ptip impairs the leukemogenic ability of HOXA9/MEIS1 cells 
(A) Transplantation schematic and survival curve for HOXA9/MEIS1-mediated 
leukemogenesis in Ptip f/f and Ptip -/- bone marrow cells. p<0.0001 (log-rank test) 
(B) Spleens taken from mice 30-days post transplantation. Mice transplanted with Ptipf/f 
HOXA9/MEIS1 cells had significantly larger spleens than those transplanted with Ptip-/- 
HOXA9/MEIS1 cells.  
(C) Tissue histology of liver and heart, and cytospins of bone marrow and peripheral 
blood taken from mice 30-day post transplantation. (Scale bars: 50μm) 
(D) Transplantation schematic and survival curve for mice received Ptip+/+; CRE-ER+/- or 
Ptip f/f;CRE-ER+/- HOXA9/MEIS1 leukemia cells. Starting from Day 14, OHT was 
injected into both groups of mice every 14 days until death. Black arrows indicate the 




Flow cytometric analysis of the bone marrows from both groups reveal a delayed 
bone marrow repopulation of Ptip -/- cells: at Day 30, 29% of the bone marrow in the Ptip 
-/- recipient mice were GFP positive, whereas nearly 100% of the bone marrow cells in 
Ptip f/f cell recipient mice expressed GFP. Moreover, Ptip -/- cells presented higher levels 
of CD11b and Gr-1 (Figure 3.4A), suggesting that they were phenotypically more 
differentiated than the Ptip-expressing cells (Figure 3.4B, upper panel). Interestingly, Ptip 
-/- cells had lower staining of Flt3 (CD135) (Figure 3.4B, lower panel), a known target of 
HOXA9, suggesting that Ptip deletion impaired the transcription activation induced by 
HOXA9 at selected targets. Ptip -/- leukemic cells also exhibited decreased proliferation 
and increased apoptosis when cultured in vitro. Altogether, these findings demonstrate 
that loss of Ptip reduces the leukemogenic potential of HOXA9/MEIS1-transformed cells. 
Together, these data highlighted the importance of PTIP in HOXA9/MEIS1-mediated 





Figure 0-4 Both PTIP and MLL4 SET domain are required for development of acute 
leukemia in mice 
(A) qRT-PCR and Western-blot showing the level of Ptip transcripts and protein 
expression in Ptip f/f and Ptip -/- HOXA9/MEIS1 cells at an early and a late time point in 
the leukemogenesis process. 
(B) Flow plot comparing the surface presentation of CD11b, Gr-1 and CD135 (FLT3) on 
Ptip f/f and Ptip -/- HOXA9/MEIS1 cells harvested at Day 30 after transplantation. 
(C) Transplantation schematic and survival curve for HOXA9/MEIS1-mediated 
leukemogenesis in Mll4-SET f/f and Mll4-SET -/- bone marrow cells. p<0.0001 (log-rank 
test) 
PTIP is also reported to participate in nuclear events other than MLL3/MLL4-
mediated histone methylation [213-215]. To verify that the prolonged survival is due to 
the disruption of MLL3/MLL4 complex and is dependent on the histone methyltransferase 
activity of MLL3/MLL4, we conducted in vivo leukemogenesis assay with targeted deletion 
of the SET-domain of MLL4, which specifically abolishes its catalytic activity. Similarly, 
Mll4-SET f/f or Mll4-SET-/- Lin- BM cells were transduced with Hoxa9/Meis1 viruses, and 
then transplanted into lethally irradiated mice. The mice received Mll4-SET-/- 




received Mll4-SET f/f cells (Figure 3.4C, p=0.0047), although the latency difference was 
less drastic than with Ptip deletion. This increase in survival indicates that the histone 
methyltransferase activity of MLL4 is required for HOXA9-induced leukemogenesis. The 
smaller survival improvement suggests that MLL3 and MLL4 possibly play a partially 
redundant role in modulating the enhancer activity in leukemic development.  
3.3.3 Loss of Ptip compromises the incorporation of H3K4me1 at HOXA9+ DE 
To alleviate the possible effects of methyltransferase redundancy, we again turned 
to the Ptip deletion model to target both MLL3 and MLL4 in the formation of de novo 
enhancers. To this end, we isolated both Ptip f/f cells and Ptip -/- cells with HOXA9/MEIS1-
mediated transformation from the mouse bone marrow at Day 30 when 50% of the Ptip f/f 
mice became morbid. We again performed H3K4me1 ChIP-seq on these cells to 
determine how Ptip deletion and consequential disruption of MLL3/MLL4 complex 
affected the enhancer landscape in HMM leukemia cells. Analysis at HOXA9+ PE and 
DE revealed that although the averaged read density remained unaffected by Ptip 
deletion at HOXA9+ PE, it decreased specifically at DE in the Ptip-deficient cells (Figure 
3.5). This distinction between the two groups of enhancers of Ptip deletion phenocopied 
that of HOXA9 inactivation, thus, it suggests that HOXA9 and Ptip-dependent H3K4 
methyltransferase collaborate to form de novo enhancers but not physiological enhancers 





Figure 0-5 PTIP is required for the formation of HOXA9+ DE 
Composite plots showing average H3K4me1 signal at HOXA9+ PE and DE in 
HOXA9/MEIS1 leukemic cells with and without Ptip deletion. Bone marrow samples 
were taken from mice 30-days post-transplantation, fixed right after red blood cell lysis. 
 
3.4 Discussion 
This chapter focuses on the candidate histone methyltransferases that 
collaborate with HOXA9 to implement the enhancer modification. We discover that 
HOXA9 directly mediates the establishment of HOXA9-regulated de novo enhancers by 
recruiting MLL3/MLL4 methyltransferases that are dispensable for the formation and 
maintenance of physiological enhancers. The molecular and functional collaboration 





3.4.1 The different recruitment mechanisms of MLL3/MLL4 
Our data suggest that HOXA9 is differentially required for targeting of the 
MLL3/MLL4 complex, and is dispensable for its binding to the physiological enhancers. 
The physiological enhancers are present in the cell-of-origin without HOXA9-mediated 
transformation, and likely exert regulatory function in hematopoietic development. 
Previous studies have shown that lineage-specific transcription factors, such as C/EBPα 
and PU.1 in macrophage [145], collectively recruit epigenetic modifiers and define the 
enhancer landscape in each lineage. The collaboration between C/EBPα and 
MLL3/MLL4 has been reported in adipogenesis [210]. Given that C/EBPα exercises 
strong binding at physiological enhancers with or without activated HOXA9, it is highly 
probable that MLL3/MLL4 is brought to those sites by C/EBPα. In fact, it is also possible 
that the recruitment of MLL3/MLL4 to HOXA9-regulated de novo enhancers is mediated 
by C/EBPα, as C/EBPα is also shown to directly interact with Hoxa9 and is required for 
transformation by Hoxa9 [61].  
3.4.2 The histone methyltransferases at de novo enhancers 
We find intensive enrichment of both H3K4me1 and H3K27ac at HOXA9 binding 
sites, as well as preferential binding of HOXA9 on active enhancers. Previous studies 
have shown that several HOX proteins as well as MEIS1 recruit the CBP-p300 complex 
at HOXA9 target sites and facilitate the incorporation of H3K27ac [61, 62], likely 
explaining the strong correlation between HOXA9 binding and H3K27ac modification. 
However, it was unknown which histone methyltransferase implements H3K4me1 and 




to the following reasons: 1) in vitro assays demonstrated that MLL1, MLL3/MLL4 are the 
major H3K4 mono-methyltransferase, while MLL1 shows slight preference for 
trimethylation [202]. 2) MLL3/MLL4 preferentially bind on enhancer regions in vivo [210, 
211, 216-219]. 3) Inhibition of MLL1 has little or no effect on cell growth in 
HOXA9/MEIS1 leukemia cells [89]. To support this hypothesis, we performed 
immunoprecipitation-Western blot, ChIP-seq assay, as well as functional analysis to 
confirm the collaboration between MLL3/MLL4 and HOXA9 at both molecular and 
functional level. Despite all these findings, we do not preclude the involvement of other 
H3K4 methyltransferases in the establishment of de novo enhancers. In fact, the 
observation that the formation of HOXA9+ DE was not completely abrogated upon Ptip 
deletion suggests a possible role for other lysine methyltransferase. However, our 
discovery of the collaboration between histone methyltransferases and HOXA9 provides 
therapeutic insights on targeting the epigenetic regulators and enhancer alterations for 







HOXA9-mediated transformation in other lineages 
4.1 Hoxa9 over expression in B lineage 
4.1.1 Background 
Although most extensively studied in AML, Hoxa9 over expression occurs in 
several subtypes of acute leukemia, as well as in a fraction of myelodysplastic 
syndromes (MDS). A large-scale microarray-based assay generated gene expression 
profiles of 2,096 leukemia and MDS patients from three continents showed that Hoxa9 
is substantially elevated both in a large subset of pro-B acute lymphoblastic leukemias 
and in a minor population of T-cell acute lymphoblastic leukemia (Figure 4.1A) [220]. 
This cross-lineage involvement suggests that HOXA9 permits and participates in the 
oncogenic transformation in a lineage-independent manner. Indeed, in vivo forced 
expression of Hoxa9 in pro-B cells blocks differentiation along the B-lineage and inhibits 
B lymphopoiesis, a phenotype similar to what is observed in the myeloid lineage [80]. 
Therefore, understanding the biological functions and target regulation of HOXA9 in 
preventing differentiation and promoting stemness will shed lights on the mechanisms of 
acute leukemias across different subclassifications.  
When B-ALL cases are subdivided based on their driving mutations, it is revealed 




and is typically silenced in other subtypes (Figure 4.1B, by Dr. Figueroa) [221]. Although 
B-ALLs with rearranged MLL or germline MLL are similar in most morphological 
characteristics, they differ significantly for their gene expression profiles. Over 
expression of Hoxa9, as well as several other Hox genes, is one of the unique 
characteristics that separate MLL-r B-ALL from other B-ALLs. In fact, MLL-r B-ALL 
bears more resemblance to MLL-r AML, since both are shown to be arrested at earlier 
hematopoietic stages than conventional AML and ALL. In addition, they also exhibit 
multilineage gene expression [112]. In light of this discovery, it is intriguing to investigate 
if the specific lineage environment affects the regulatory function of HOXA9. In this 
study, I show that the over expression of Hoxa9 and Meis1, as well as Hoxa9 alone, 
transforms progenitors into the B-lineage, although they experience lineage conversion 
when transplanted into recipient mice. In the B-precursor cell line, HOXA9 
predominantly binds to active distal elements, which are also enriched for B-lineage 
specific transcription factor motifs. Moreover, Hoxa9 over expression in the B lineage 





Figure 0-1 The expression of Hoxa9 in acute leukemia 
 (A) Box plot showing Hoxa9 expression in different subtypes of acute leukemia. Data 
set from [220]; plot generated by https://www.oncomine.org/. 
(B) Box plot showing Hoxa9 expression in B-ALLs with different genetic aberrations. 
TCF3: t(1;19)(q23;p13.3) translocation. Ph: t(9;22)(q34;q11) translocation. CRLF2: 
cytokine receptor–like factor 2 rearrangement, MLLr: MLL rearrangement at 11q23. 
ETV6: t(12;21)(p13;q22) translocation. Bar plot generated by Dr. Figueroa. 
4.1.2 Materials and Methods 
B cell differentiation 
Lin- BM was harvested according to the protocol in Chapter 2.2: Cell lines. OP9 
cells were seeded 24 hours before the experiment. Lin- BM culture was then transferred 
on to OP9 cells with cytokine supplements: Flt3L 5ng/mL, IL-7 5ng/mL. The culture was 
transferred onto fresh OP9 cells every 3-4 days. CD19+, B220+ cells emerged after 
around two weeks. 
in vivo leukemogenesis assay 
This assay protocol was modified from in Chapter 3.2: in vivo leukemogenesis 




C57BL/6J mice together with 2.5x104 Ficoll (F4375, Sigma) purified fresh bone marrow. 
Mice were maintained on antibiotic water for two weeks. The mice were sacrificed when 
they became moribund. Visceral organs (liver, lung heart and spleen) and bone (tibia 
and sternum) were collected for histological and flow cytometric analysis. 
ChIP, ChIP-seq and RNA-seq analysis 
These analyses were performed as described in Chapter 2.2: ChIP, ChIP-seq 
analysis, Peak annotation and RNA-seq analysis. 
4.1.3 Results and Discussions 
Generation of Hoxa9-transformation B-precursor cell lines 
First, we tested the previous claim that progenitors immortalized by Hoxa9 alone 
are myeloid-restricted, while co-expression with Meis1 confers lymphoid differentiation 
potential on the immortalized cells [109]. To this end, I used an in vitro B cell induction 
protocol to force differentiation along the B lineage. This was achieved by transducing 
Hoxa9 or Hoxa9 plus Meis1 into Lin- BM, and culturing them in B cell specific conditions 
(with IL-7, FLT3L and OP9 stromal cells) (Figure 4.1A). The differentiation progress was 
compared to that of the empty vector (EV)-transduced progenitors. As shown in Figure 
4.1B, at Day 7, a greater portion of Hoxa9/Meis1 co-transduced cells remained lineage-
negative, while large percentage of EV and Hoxa9 alone were positive for myeloid 
markers. At Day 11, subpopulations of CD19-positive B cell started to emerge in all 
three groups, whereas the myeloid population first disappeared in the Hoxa9/Meis1-
transduced group. At Day 15, all three groups became predominately positive for CD19, 




compartment remained unchanged until EV cells underwent apoptosis and died out 
(Figure 4.1B). Based on this result, it is clear that both Hoxa9 alone and Hoxa9/Meis1 
co-transduced cells retain the potential of lymphopoiesis. Hoxa9 cells developed into 
the B-lineage at a similar rate as the control cells, suggesting that HOXA9 does not 
actively prevent early B-lymphopoiesis. The observed difference between Hoxa9 only 
and Hoxa9/Meis1 cells in the previous study was possibly reflected in their 
differentiation kinetics: by upregulating IL-7r and FLT3 [109], Meis1 over expression 
provides more surface receptors for B cell-inducing cytokines or other environmental 





Figure 0-2 The generation and characterization of HOXA9-transformed B lineage cells 
 (A) The differentiation schematic. (B) Flow cytometry analysis on the differentiation 
progress of the three types of in vitro induced B lineage cells. The population 
constitution indicated with CD11b (myeloid) and CD19 (B cells) (C) The surface marker 
characterization of pro-B cells and HMB cells with CD19, B220, c-Kit and CD43. (D) 
Relative RNA expression of Rag1, TdT, Ebf1 and Pax5 in HMM, HoxB and HMB cells.  
Hoxa9 and Hoxa9/Meis1 cells were then characterized using a series of cell 
surface markers and transcription factors to indicate their differentiation stages. Both 
cells were largely B220+ and CD19+ (Figure 4.1C and data not shown). They also 
expressed similar level of TdT, Rag1, Ebf1 and Pax5 (Figure 4.1D), while these genes 




of Pax5 expression, suggests that the two types of cells have entered the lineage-
committed stage of B cell differentiation. Based on the c-Kit positivity, we classified both 
cells as at pro-B stage. Hoxa9 alone and Hoxa9/Meis1-transformed B precursors are 
thus referred to as HoxB and HMB cells respectively. Although having similar 
immunophenotype, HoxB cells constantly experienced apoptosis and were completely 
dependent on OP9 stromal cells for proliferation. By contrast, HMB cells proliferated 
well with or without OP9, and could propagate in vitro for at least three months without 
undergoing apoptosis, suggesting that these cells were fully immortalized. HMB cells 
thus were utilized in the downstream analysis. 
Lineage conversion of HMB cells 
The leukemogenic ability of HMB cells were then analyzed using in vivo assays. 
These cells were transplanted into lethally irradiated syngeneic mice together with 1/10 
count of fresh bone marrow to overcome the irradiation-induced lethality. HMB recipient 
mice developed acute leukemia within the same timeframe as compared with HMM 
recipient mice (Figure 4.3A). Surprisingly, the leukemic bone marrow harvested from the 
HMB mice showed a different phenotype than the HMB transplant: they lost the B cell 
marker, CD19, and acquired mature myeloid markers, CD11b and Gr-1 (Figure 4.3 B 
and C). This lineage conversion was inconsistent with the pro-B differentiation stage, 
since in normal hematopoiesis, Pax5-expressing pro-B cells would have lost 
multilineage developmental potential. To determine whether it was bona fide 
transdifferentiation, or simple clonal expansion of the few lineage-uncommitted/myeloid 
leukemia stem cells, we tested for the genetic rearrangement at the immunoglobulin 




transplantation leukemic cells would have rearranged genetic configuration at the IgH 
locus, since they have entered the B cell fate previously; in contrast, the straight 
myeloid differentiation would not alter the genetic configuration at this locus. 
Surprisingly, HMB cells indeed experienced the transdifferentiation phenomenon which 
was confirmed with this clonality test. Both pre- and post-transplantation HMB cells had 
the DH-JH rearrangement, while HMM had the non-rearranged configuration as the 
germline cells (Figure 4.3D). This result indicates that HMB cells are featured with 
lineage infidelity, and their immunophenotype can be switched by the environmental 
inducers. It also suggests that Hoxa9/Meis1-mediated transformation provides the cells 
multi-lineage potential, even when they are phenotypically more differentiated. Similar 
lineage conversion has been reported with FACS-isolated lymphoid lineage 
Hoxa9/Meis1 cells from leukemic mice, and it was suggested that the tumor-initiating 
activity is independent of their stable immunophenotypes [110]. Altogether, it is highly 
plausible that Hoxa9/Meis1-mediated leukemias have a conserved transformation 
mechanism that is uncoupled to the lineage specification. The exact mechanisms by 





Figure 0-3 The in vivo lineage conversion of HMB cells 
 (A) The survival curves of mice transplanted with HMM and HMB cells respectively. (B) 
The flow plot showing CD19 positivity, indicative of B lineage commitment, of HMB cells 
before transplantation. (C) The cell surface markers of the post-transplantation HMB 
leukemic cells, showing the positivity of CD11b and Gr-1. (D) The genetic configuration 
of IgH locus in germline (GL), HMM, pre- and post-transplantation HMB cells.  
 
The genome-wide binding of HOXA9 
Previously, HOXA9 has been found in HMM cells to primarily bind promoter-
distal regulatory elements [54, 61]. To determine the genome-wide localization of 
HOXA9 in HMB cells, we performed chromatin immunoprecipitation sequencing (ChIP-
seq) using an anti-HA antibody to target the HA-tag fused to HOXA9. With the 18,601 
high-confidence peaks, we observed similar preferential binding to promoter-distal 
regions: while 26% (n = 4849) occurred within promoter regions, 70% (n=13033) 
occupied intergenic and intronic regions (Figure 4.4A). To relate these binding sites to 
chromatin states, we performed ChIP-seq for key histone modifications, including 




enriched with H3K4me1 and H3K27ac, but depleted of H3K27me3 (Figure 4.4B), similar 
to the signature in HMM cells. Indeed, the majority (80%) of the promoter-distal peaks of 
HOXA9 overlapped with putative active enhancers, while limited binding (10% and 2%) 
was found on primed enhancers and poised enhancers (Figure 4.4C). Comparison of 
HOXA9 binding in the two cell types identified only 1,839 common peaks, which 
represent 28% and 9.9% of total HOXA9 target sites in HMM and HMB cells, 
respectively (Figure 4.4D). Lineage-specific HOXA9 binding was further confirmed with 
motif enrichment analysis. As shown in Figure 4.4E, sequence motifs of B-cell specific 
transcription factors EBF1 and TCF3 were overrepresented at HOXA9 binding sites in 
HMB cells, while those of myeloid specific transcription factors, such as C/EBP and ETS 
family factors, were enriched in HMM cells, suggesting that the lineage-specific 
transcriptional milieu plays a role in HOXA9’s localization. 
 
Figure 0-4 The genome-wide binding of HOXA9 in HMB cells 
 (A) The genomic distribution of HOXA9 in HMB cells. (B) Composite plot showing 
average per bp density of HOXA9, H3K4me1, H3K27ac and H3K27me3 at HOXA9 




distribution among different enhancer states at HOXA9’s promoter-distal binding sites. 
These sites are preponderantly associated with active enhancer signatures. (D) 
Physical overlap of HOXA9 peaks in HMM and HMB cells. (E) Motif analysis of 6,578 
and 18,601 HOXA9 peaks in HMM and HMB cells. 
 
Global epigenome changes in HMB cells 
 Enhancers constitute the regulatory code that drives cell type-specific gene 
expression. Since HMB cells are capable of undergoing lineage conversion, we 
wondered whether the lineage infidelity was reflected in their enhancer landscape. To 
this end, we compared the global H3K4me1 profiles of HMB and HMM cells with their 
respective culture controls, as well as the cell types in normal hematopoietic hierarchy. 
Surprisingly, hierarchical clustering based on the global H3K4me1 dynamic profile 
showed that HMB cells share the highest similarity with Pro-B cells, but not HMM cells, 
suggesting that HMB cells still largely maintained the enhancer landscapes of the cell-
of-origins (Figure 4.5A). When closely inspecting the 116,182 H3K4me1 regions in all 
20 cell types, we discovered that two non-overlapping clusters of regions exhibited high 
signal enrichment within HMB (Cluster 1) and HMM cells (Cluster 2), respectively, but 
were unmarked in any other cell types, which are consistent with the de novo enhancers 
identified in Chapter 2 (Figure 4.5B). These data imply that although HOXA9/MEIS1-
dependent AML and B-ALL may be able to transdifferentiate and induce aggressive 
leukemia in mice, their epigenomes are still largely determined by their lineage 
specification. Most importantly, these two types of cells form distinct repertoires of de 
novo enhancers after transformation, suggesting that the changes in enhancer 




 HOXA9 facilitates the formation of cancer-specific enhancers in HMM cells. In 
accord with this finding, we found that among the 12,378 HOXA9-bound enhancers in 
HMB cells, 1,473 had no H3K4me1 prior to transformation in pro-B cells, the normal 
lineage counterparts for HMB (Figure 4.5C). Interestingly, these novel enhancers also 
lacked H3K4me1 mark in other normal hematopoietic cells (Figure 4.5D), suggesting 
that like the HOXA9+ DE in HMM cells (Chapter 2.3.3), these enhancers are created de 
novo specifically during the leukemic transformation process. Most strikingly, GO 
analysis showed that comparing with the HOXA9-regulated physiological enhancers, 
these de novo enhancers were also enriched for multiple embryonic development 
pathways (Figure 4.5E). This indicates that the ectopic activation of early developmental 
pathways is a conserved feature of HOXA9-mediated transformation. It is fascinating 
that HOXA9 resorts to the same pathways to drive transformation, but employs different 
players of the same pathways in different lineages. The exact mechanisms by which the 






Figure 0-5 HOXA9 targets a subset of de novo enhancer in HMB cells 
 (A) Clustering dendrogram of cell types based on H3K4me1 profiles showing the 
association of HMM and HMB cells with the untransformed counterparts in their 
respective lineages. Color code: green for multipotent progenitors, orange for myeloid 




red for erythroid lineage. (B) Heatmap showing 101,413 hematopoiesis and 
leukemogenesis enhancers clustered with K-means (K=16) using the normalized read 
count at each enhancer region. Cluster 1 in HMB and Cluster 2 in HMM indicate the 
unique H3K4me1 signature in the transformed HM cells. (C) Heatmap depicting the 
signal intensity of HOXA9 in HMB and H3K4me1 in ProB and HMB at 12,389 HOXA9-
bound distal regulatory elements. The rows show ±3kb regions around HOXA9 peak 
center. The 12,389 regions are separated into two categories, 1473 HOXA9+ DE and 
10905 HOXA9+ PE based on the differential H3K4me1 modification status. (D) 
Heatmap depicting signal intensity of H3K4me1 at 10905 HOXA9+ PE (upper panel) 
and 1473 HOXA9+ DE (lower panel) in normal hematopoietic cells of different 
differentiation stages into the B lymphocyte maturation. (E) Gene Ontology terms for PE 
and DE-associated genes with the corresponding Benjamini p-values. Pathways 
specifically enriched with DE are shown on top. 
    
4.2 Hoxa9 over expression in adipogenesis 
4.2.1 Background 
A previous study in our lab discovered that in HOXA9/MEIS1-driven AML cells 
(HMM cells), adipogenesis and PPARγ signaling are two of the most enriched pathways 
upregulated upon HOXA9 inactivation (Figure 4.6 A and B). It suggests that in the 
myeloid lineage, HOXA9 represses the adipogenic fate, and its inactivation results in 
reactivation of the entire pathway.  
It is an interesting observation, since adipogenesis involves sequential activation 
of a series of transcription factors, including C/EBPα, C/EBPβ, C/EBPγ and STAT5 
[222], which are also lineage-specifying transcription factors in myelopoietic 
differentiation. In fact, although macrophages and adipocytes are morphologically 
different, studies have shown that they may share some similar features. First, 
numerous inflammatory factors, such as tumor necrosis factor alpha (TNFα), are 




also develop phagocytic activity upon infection, and this response disappears when they 
differentiate into adipose tissue [225]. Moreover, not only do preadipocytes and 
macrophages share common immunophenotypic properties, but they can also 
transdifferentiate into the other lineage under regular physiological conditions [226, 
227]. Most importantly, PU.1 and C/EBPα/β efficiently convert pre-adipocytes into 
macrophage-like cells [228], exemplifying the significance of availability and dosage of 
lineage-determining factors in cell fate specification.  
 
Figure 0-6 HOXA9 inhibits adipogenesis pathways in HMM cells, and is upregulated in a 
particular type of liposarcoma. 
(A-B) Gene Set Enrichment Analysis of the expression profiles of HOXA9 inactivated 




pathway (A) and PPAR signaling pathway (B). Figure generated by Cailin Collins and 
Jingya Wang, unpublished results. (C-D) Over expression of HOXA9 is consistently 
associated with myxoid/round cell liposarcoma in two studies. Box plot generated by 
Oncomine. 
Hox genes are also involved in the regulation of adipogenesis. Hoxa9, in 
particular, is highly expressed in the brown adipose tissue; in white adipose tissue, it is 
found significantly upregulated after fat loss [229, 230]. Apart from its role in adipocyte 
development, Hoxa9 over expression is specifically associated with one subtype of 
liposarcoma, the myxoid/round cell liposarcoma (Figure 4.6 C and D). Thus, 
understanding the role of HOXA9 in the adipogenesis process has both physiological 
and pathological significance. In light of these studies, we used the adipogenesis 
system to study the functions of HOXA9, and sought to understand whether HOXA9 
employs cell type specific or common mechanisms to regulation gene expression and 
cellular differentiation. 
4.2.2 Materials and Methods 
Induction of 3T3-L1 into adipocyte-like cells  
3T3-L1 cells (CL-173, ATCC) cells were seeded in a six-well plate at a density of 
3.5x104 cells/well, and grown until reaching 70% confluency. To initiate differentiation, 
cells were remove from DMEM media and added MDI induction medium [0.5 mM IBMX, 
1 µM dexamethasone, 10 µg/mL insulin] 2 mL/well. After 3 days, MDI medium was 
removed and replaced with insulin medium [10 µg/mL insulin] 2mL/well. After 7 to 10 
days, cells were differentiated into adipocyte like cells. 




 HOXA9-ER plasmid was transfected in 3T3-L1 fibroblast cells using FuGene 6. 
Transfection medium was replaced after 24hrs. To activate HOXA9, 100nM OHT was 
added together with MDI medium or at different time points during differentiation to 
monitor the effect on adipogenic differentiation. 
Oil-Red-O staining 
The Oil-Red-O stock solution was prepared by dissolving 300 mg of Oil-Red-O 
powder (0-0625, Sigma) in 100 ml of 99% isopropanol. Working solution was then 
prepared by adding 20mL of water to 30mL of Oil-Red-O stock solution and filtered with 
filter paper. Cells were fixed with 10% formalin at R.T. for 30min, and washed with 
distilled water twice. Then isopropanol was added to the cells for 5min, followed by the 
Oil-Red-O working solution for 5min. The monolayer was then rinsed with water. Oil-
Red-O can be solubilized with isopropanol and quantified with spectrometer. 
RNA extraction and RT-qPCR 
RNA was purified using the Qiagen RNeasy kit with on-column DNase treatment. cDNA 
was generated using Superscript III RT and target gene expression was determined relative 
to β-actin using Invitrogen Taqman probe sets . 
4.2.3 Results and Discussion 
 Since HOXA9 inhibits the adipogenic program as well as Pparγ expression in 
myeloid lineage cells, we first examined whether HOXA9 plays the same role in pre-
adipocytes. This was achieved by overexpressing Hoxa9 in mouse embryonic 
fibroblasts 3T3-L1 cells, which can be induced into adipocyte-like cells with chemical 




inhibited adipogenic development. As shown in Figure 4.7A. After 12 days, without 
HOXA9 activation, 3T3-L1 fully adopted the adipogenic fate and accumulated fatty acid 
droplets in the cytoplasm. In contrast, HOXA9 overexpressing cells retained the 
fibroblast morphology even after chemical induction. Using oil red o staining, the 
inhibition effects were quantified. It was shown in Figure 4.7 B and C that the lipid 
accumulation was significantly impaired in the group with HOXA9 activation, whereas 
the HOXA9 inactivated group as well as the empty vector control cells had similar level 
of cytosolic lipid content. This evidence indicates that HOXA9 indeed inhibits the 
differentiation progression of pre-adipocytes, which is consistent with the pathway 
inhibition observed in myeloid lineage cells.  
 
Figure 0-7 HOXA9 inhibits adipogenesis in pre-adipocytes. 
 (A) The cell morphology of the HOXA9 inactivated (EtOH) and HOXA9 activated (OHT) 




fluorescent channel (GFP). (B) Oil red o staining of the EtOH and OHT treated cells 
after adipogenic differentiation. (C) Quantification of the staining result in (B). 
 In normal adipogenesis, a series of transcriptional events are initiated right after 
differentiation induction. The expression of Myc, Jun and Fos surges within 1 hour of 
MDI medium addition, while Cebpb and Cebpd are also mildly upregulated. 
Subsequently, C/EBPβ and C/EBPδ together induce the expression of Cebpa and 
Pparg, which in their turn form a positive feedback loop and induce the expression of 
adipocyte specific genes [231]. Given that HOXA9 inhibits the adipogenesis program, 
we next examined whether HOXA9 over expression affected the transcription cascade 
in the differentiation process. RNA expression profiling at different time points showed 
that the EtOH treatment group followed the standard pattern of transcriptional 
regulation. However, with HOXA9 activation, Cebpb was significantly upregulated, while 
the upregulation of Pparg was hampered (Figure 4.8). Since PPARγ is one of the most 
critical determining factor of adipogenesis, and is indispensable for adipocyte-specific 
gene expression and fat droplet formation, its reduced activation may explain the lack of 
differentiation potential of the Hoxa9-overexpressing fibroblasts. Although the 
mechanism by which HOXA9 inhibits the expression of Pparg is not clear, we postulate 
that the over abundant HOXA9 may impede the correct assembly of transcriptional 
machineries at Pparg regulatory elements which is essential for the transcription 
initiation. Pparg gene has multiple functional enhancers, whose transformation from 
close to open state requires a series of chromatin events [222]. The overactivated 
HOXA9 perhaps interferes with the critical steps of the chromatin state modulation at 
Pparg enhancers, so that Pparg upregulation was not achieved properly. The exact 





Figure 0-8 The expression of key adipogenic transcription factors with or without 
HOXA9 activation 
Over the 9-day course, the expression of indicated genes were measured. Only Pparg 







Concluding remarks and future directions 
 Despite the increasingly refined knowledge in the targetable mutations and 
mechanisms of acute leukemia, there have not been major advances in targeted 
therapies for leukemias with HOXA9 over expression. Thus, there is an urgency to 
understand how HOXA9 achieves transformation in multiple subclassifications of 
leukemia to guide future therapeutic development. Recently, several studies employed 
high-throughput sequencing technologies to delineate the genome-wide binding sites of 
HOX proteins and gene regulatory networks, which have undoubtedly shed light on 
HOX biology. However, these works have been more descriptive than mechanistic, and 
fundamental understanding of HOXA9-mediated transformation mechanisms is still 
mostly lacking. 
Our lab has worked to better define the mechanisms of HOXA9-mediated 
transcriptional regulation and transformation. These studies showed that HOXA9 
predominately targets active enhancer regions, and a large subset of its binding sites 
are co-bound by lineage-specific transcription factors. To investigate these co-
occurrences and correlations, I sought to establish a causative role of HOXA9 in altering 
the enhancer landscapes. To this end, I found that in both myeloid and lymphoid 




their cell-of-origin, but also acquire novel enhancers at specific regions that have no 
enhancer modifications or lineage-factor binding in any normal hematopoietic cells. I 
found that these novel enhancers regulate the activation of a leukemia-specific 
transcription program. Further, HOXA9 executes a pioneer role and its binding is 
essential for the establishment of these novel regulatory elements: it mediates the 
assembly of an enhancer-binding complex by recruiting both the myeloid lineage factor, 
C/EBPa, and the histone methyltransferase complex, MLL3/MLL4 complex. The 
complex assembly at these de novo regions is critical for the implementation of the 
enhancer characteristics and the activation of the nearby genes. In contrast, HOXA9 is 
dispensable for both transcription factor binding and incorporation of the H3K4me1 
mark at normal physiological enhancers; it likely exhibits opportunistic binding and is 
nonessential for the associated gene activation. This interesting distinction can be 
summarized into a diagram in Figure 5-1. Together, these findings highlight HOXA9’s 
critical role in establishing an enhancer landscape in support of the leukemia identity 





Figure 0-1 Model for HOX-regulated enhancer formation and gene regulation in 
leukemia development. 
The work presented in this thesis brought forward the hypothesis that HOXA9’s 
regulatory role in leukemia is associated with the establishment of de novo enhancers, 
where it recruits other factors and chromatin regulators in the activation of a 
leukemogenic transcription program. 
There remain open questions pertaining to HOXA9’s pioneer role in the 
establishment of active regulatory elements. First, to confidently claim HOXA9 as a 
pioneer factor in leukemia, the gold standard – the DNase accessibility analysis – has to 
be applied. Based on the results of Abd-B in Drosophila (Chapter 1.2.4), it is highly 
likely that HOXA9 acts similarly as its ortholog and targets both pre-accessible DNA and 
nucleosome-bound DNA. Given that HOXA9 forms multi-subunit complexes with MEIS1 
and PBX1, and collaborates with them for DNA binding specificity and target gene 
regulation, it is thus interesting to examine how the two co-factors contribute to the 
chromatin remodeling function of HOXA9. Given that HOXA9 alone has limited 
transformation potential and only gives rise to leukemia after an extended period of 
time, I speculate that the synergistic interaction with MEIS1, if not PBX1 as well, is 




heterodimer, the HOXA9-MEIS1 complex may have more diversified functions, form 
stronger interaction with transcriptional and epigenetic machineries, and regulate the 
downstream targets in concert. 
Second, it is now relatively clear that HOXA9 mediates the establishment of de 
novo regulatory elements in leukemogenesis, and is required for their stability. 
However, HOXA9’s role at the normal hematopoietic enhancers (i.e. HOXA9+ PE in 
Chapter 2) remains to be fully understood. The cumulative effect at HOXA9-bound 
physiological enhancers is insignificant, which means that HOXA9 over expression or 
inactivation does not result in a prominent up- or down-regulation of those genes as a 
whole. However, the overall effect can be cancelled out when similar numbers of genes 
are up- and down-regulated. Considering that a significant portion of HOXA9+ PE-
associated genes are differentially regulated, it is plausible that HOXA9 employs 
divergent mechanisms to drive either activation or repression of those target genes. 
Along this line, it is unclear what gene repression mechanism HOXA9 may use, if at all, 
in mediating the inhibition of myeloid differentiation program or immune responses in 
AML cells. Alternatively, it is also possible that HOXA9 exhibits pure opportunistic 
binding at the hematopoietic enhancers, and is fully dispensable for gene regulation at 
those sites (Figure 5-1).  
Besides offering mechanistic insights, this thesis study has profound implications 
in the therapeutic development for leukemias with HOXA9 over expression. It suggests 
that targeting the multicomponent complex assembly at the de novo enhancers 
constitutes a novel avenue in the treatment of these acute leukemias. As shown in 




of de novo enhancers, and significantly delays leukemia progression in mice. Therefore, 
inhibitors can be designed to target the catalytic activity of MLL3/MLL4, as well as its 
recruitment by HOXA9, and consequently block the activation of leukemogenic 
transcription program. Notably, MLL3/4 has a critical role in gene regulation as well as 
in tissue development and homeostasis. For this reason, therapeutic inhibition of its 
enzymatic activity would have to be highly specific and tightly controlled. A more 
targeted approach is to block the interaction surface between HOXA9 and the MLL3/4 
complex, which requires further studies to fully characterize. Moreover, as mentioned in 
Chapter 3, a wide variety of mechanisms can lead to the incorporation of H3K4me1 
mark at enhancer sites, and redundant mechanisms may function in concert to establish 
the leukemia-specific enhancer landscape. Thus, the clinical efficacy of targeting the 
MLL3/MLL4 complex for leukemia treatment needs careful investigation. Despite these 
caveats, this thesis study offers immense prospects for targeting the MLL3/MLL4 
histone methyltransferase in leukemia, and provides mechanistic support for developing 
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